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ABSTRACT 
 
Tiffany L. Williams: Modulation of PSMA Splice Variants using Splice Switching 
Oligonucleotides in Prostate Cancer Cells 
(Under the Direction of Ryszard Kole, Ph. D.) 
 
The Prostate Specific Membrane Antigen (PSMA), a product of the GCPII 
gene, is highly expressed as a largely extracellular membrane-anchored protein 
in malignant prostate tissues and in non-prostatic tumor neovasculature.   
Alternatively spliced variants of PSMA include the PSM’, PSMA∆6, and 
PSMA∆18 transcripts.  PSM’ is produced by use of an alternate upstream 5’ 
splice site in exon 1 and produces a cytoplasmic localized protein missing 
PSMA’s transmembrane domain.  The PSMA/PSM’ splice ratio changes from 
predominately PSM’ in normal and benign prostate tissues to predominately 
PSMA in prostate cancer.  Variants PSMA∆6 and PSMA∆18 are produced by 
exon exclusion of exons 6 and 18, respectively, by the splicing machinery.  If 
properly translated, PSMA∆6 protein retains its membrane targeting, but lacks 
PSMA’s enzymatic and dimerization domains; PSMA∆18 lacks only the 
dimerization domain.  Both exon exclusion products should not produce 
functional proteins. 
Extensive studies have shown the ability of antisense oligonucleotides to 
target specific splicing elements in pre-mRNA to alter alternative splicing patterns 
by interfering with splicing machinery sequence recognition.  Therefore, 
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antisense based splice switching oligonucleotides (SSOs) were targeted at or 
near the 5’ splice sites of exons 1, 6, and 18  to alter PSMA splicing patterns by 
decreasing full length PSMA transcript levels and increasing PSM’, PSMA∆6, 
and PSMA∆18 variant levels, respectively in LNCaP prostate cancer cells.  We 
hypothesized that altering the PSMA/PSM’ splicing ratio would affect specific 
properties of LNCaP malignancy including cellular proliferation and apoptosis 
levels.  Also, splice switching to PSMA∆6 and PSMA∆18 variants while causing a 
decline in PSMA would aid identifying effects produced by a decline in PSMA 
alone.  
Studies in this dissertation demonstrate that treatment of LNCaP cells with 
SSOs did modulate splicing of PSMA pre-mRNA from the full length PSMA splice 
variant to three splice variants: PSM’, PSMA∆6, and PSMA∆18 variants.  
Application of SSOs decreased membrane PSMA mRNA and protein levels and 
increased PSM’, PSMA∆6 and PSMA∆18 transcript levels. As a result, PSM’ 
protein was translocated to the cytoplasm while switching to PSMA∆6 and 
PSMA∆18 downregulated PSMA expression. NAALDase assays confirmed 
splice switching at the protein functional level and showed that PSM’ retained 
enzymatic activity.  However, we were not able to determine any specific effects 
of splice switching on LNCaP malignancy as detected by cellular proliferation and 
apoptosis. 
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CHAPTER 1 
 
Introduction 
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I. Pre-mRNA splicing 
Almost all eukaryotic mRNA transcripts contain intronic sequences with 
noted exceptions being histone and heat shock transcripts (Kedes 1979; 
Hentschel and Birnstiel 1981; Hunt and Calderwood 1990).  Moreover, the 
presence of introns can positively influence gene expression (Gruss, Lai et al. 
1979; Brinster, Allen et al. 1988; Palmiter, Sandgren et al. 1991).  The introns 
must be removed and exons precisely and efficiently connected to ensure gene 
sequence accuracy.  It is estimated that more than 90% of pre-mRNA sequence 
is intronic and therefore removed from mature mRNA (Lander, Linton et al. 
2001).  Pre-mRNA splicing is the process by which nuclear factors act on pre-
mRNA to remove introns and connect exons aiding in the transition to mRNA.  
Cis- and trans- splicing are the two types of pre-mRNA splicing that occur within 
the eukaryotic cell: cis-splicing is the more common type wherein a single pre-
mRNA molecule is involved (Moore and Query 1993; Burge, Tuschl et al. 1999); 
the rarer trans-splicing requires the interaction of separate pre-mRNA sequences 
joined at specific exons (Konarska, Padgett et al. 1985; Solnick 1985; Mayer and 
Floeter-Winter 2005).   
A. Splicing elements & factors 
Splicing elements 
Pre-mRNA splicing, i.e., the removal of the non-coding introns, and the 
subsequent joining of the coding regions, or exons, occurs at the exon-intron 
junctions termed splice sites, via two trans esterification steps (Moore and Query 
1993).  The four pre-mRNA sequences necessary for splicing are the 5’ splice 
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donor site, 3’ splice acceptor site, the intronic branch point, and a polypyrimidine 
sequence upstream of the branch point.   These splicing elements have general 
consensus sequences utilized by the splicing machinery for effective 
identification of introns and exons (Fig. 1.1).  Most of the nucleotides in each 
consensus sequence are degenerate, that is they can be replaced by other 
nucleotides and the element can still be recognized for splicing.  Element 
strength is partially determined by adherence to consensus, but the inherent 
degeneracy is key in the process of alternative splicing (described later in more 
detail).  Of the 5’ and 3’ splice site consensus sequences (C37 A58 G78 /G100 U100 
A57 A71 G84 U47 and 12Y70 NC74 A100 G100 /G49, respectively), only two 
nucleotides, GU in the donor 5’ splice sites and AG in the acceptor 3’ splices 
sites, are conserved in essentially all splice sites examined (Y=pyrimidine, N= 
any nucleotide, subscript number= percent presence of the nucleotide at that 
position).  The remaining nucleotides of the consensus splice site sequences are 
represented at lower frequencies, resulting in functional splice sites with 
divergent sequences.  Given the short and poorly conserved nature of the splice 
site sequences, the mechanism of selection of authentic splice sites among the 
many similar sequences that constitute cryptic and pseudo splice sites is still not 
completely understood.  It is the degenerate branch point that determines which 
3’ splice site is utilized (Smith, Porro et al. 1989).  The branch point is seven 
nucleotides long with an YNYURAY consensus sequence (Y=pyrimidine, R= 
purine, N= any nucleotide, A= invariant adenine nucleotide) and is located 18 to 
40 nucleotides upstream of the 3’ splice site (Zhuang, Goldstein et al. 1989); this  
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5’ splice (donor) site = C37A58G78/G100U100A57A71G84U47
3’ splice (acceptor) site = 12Y70NC74A100G100/G49
Branch Point = YNYURA100Y
Polypyrimidine tract 
Exonic Splicing Enhancers/Silencers
Intronic Splicing Enhancers/Silencers
Pre-mRNA
Exon 1 Exon 2
mRNA
Exon 1 Exon 2
A.
B.
Figure 1.1.  Pre-mRNA splicing elements.   
 
A) Pre-mRNA sequences contain several intronic and exonic cis splicing 
elements that are recognized by the splicing machinery to produce mature 
intronless mRNA.  B) Major splicing elements are listed.  The 5’ splice site, 3’ 
splice site, and branch point are shown with their corresponding consensus 
sequences; subscript number is the percentage that nucleotide is found at that 
position in the consensus sequence; bold letters indicate invariant nucleotides. 
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range of location and sequence variability can lead to the identification of 
different branch points by the splicing machinery (Burge, Tuschl et al. 1999).  
Efficient recognition of suboptimal elements may be improved by additional 
sequences such as exonic or intronic splicing enhancers (ESEs, ISEs) (Hertel, 
Nomikos et al. 1997; Maniatis and Tasic 2002). There are also counteracting, 
regulatory sequence elements, known as exonic and intronic splicing silencers 
(ESSs, ISSs), which promote exon exclusion (Caputi, Mayeda et al. 1999; Chen, 
Kobayashi et al. 1999; Del Gatto-Konczak, Olive et al. 1999; Sironi, Menozzi et 
al. 2004) (Fig. 1.1).   
snRNPs and SR proteins 
The sequence elements involved in splicing are recognized by trans- 
factors including small nuclear ribonuclear proteins (snRNPs) and a number of 
other splicing factors such as heterogeneous nuclear ribonucleoproteins 
(hnRNPs) and SR proteins (see Blencowe 2000; Cartegni, Chew et al. 2002; 
Black 2003 for recent reviews), which contain arginine-serine-rich (RS) motifs 
(Blencowe, Bowman et al. 1999; Hastings and Krainer 2001). 
Small nuclear RNAs are active within larger ribonucleoprotein complexes 
called snRNPs.  Five snRNPs: U1, U2, U4, U5, and U6, have been identified as 
important factors in spliceosome formation, composition and function (Lerner, 
Boyle et al. 1980 and reviewed in Guthrie and Patterson 1988; Kramer 1996).  
Both the RNA and protein components of these snRNPs make key contacts to 
RNA and other splicing proteins, including: SR proteins, hnRNPs and many other 
miscellaneous proteins.  By studying evolutionarily early type II splicing reactions 
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like those seen in the organelles of bacteria and the more recent production of a 
protein-less spliceosome, it is assumed that snRNPs evolved from an earlier 
RNA based splicing apparatus (Valadkhan 2005).  The U1, U2, and U5 snRNPs 
exist as single particles in which individual snRNAs are complexed with Sm and 
other proteins unique to that snRNP.  The U4 and U6 snRNAs are bound 
together in the nucleus as one snRNP (Bringmann, Appel et al. 1984; Hashimoto 
and Steitz 1984).  Specifics of snRNP involvement in the splicing process are 
detailed later. 
SR family proteins have N-terminal RNA-recognition motifs (RRM) and a 
serine/arginine (RS) rich C-terminal domain.  The RRMs directly bind RNA and 
the RS region is involved in protein-protein interactions, such as recruiting other 
proteins to the splicing complex, and splice site pairing (Wu and Maniatis 1993; 
Min, Turck et al. 1997).  SR proteins may also directly contact pre-mRNA at the 
branch point and 5’ splice site (Shen, Kan et al. 2004).    
The concentrations and the ratios between these splicing factors in 
different cell types and tissues clearly control splicing.  For example, hnRNPA1 
acts as an antagonist of the SR protein SF2/ASF, which functions in defining the 
5’ splice site proximal to the downstream 3’ splice site by interacting with U1 
snRNP. Higher A1/SF2 ratios shift splicing towards an alternative, distal 5’ splice. 
Notably, this ratio can vary 100-fold in different tissues (Caceres, Stamm et al. 
1994).  Overall the combinatorial interactions of the factors with the sequence 
elements in pre-mRNA determine the tissue-specific expression of most pre-
mRNAs (Smith and Valcarcel 2000; Roberts and Smith 2002).  As a result of 
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these complex interactions there are a number of different alternative splicing 
events including exon skipping, inclusion of alternative exons; and use of 
alternative splice donor and acceptor sites and intron retention.  
B. Nuclear cis-splicing: mechanism and the spliceosome  
 The understanding of pre-mRNA splicing has evolved with the use of in 
vitro splicing systems.  New information continues to become available and the 
understanding of the complete mechanism of nuclear splicing is still in flux.  In 
this section, I will summarize the current knowledge of spliceosome formation 
and the splicing reaction during cis-splicing in nuclear introns as described in 
Genes VII (Lewin 2000) and several primary and review articles. 
Lariat structure 
The splicing reaction occurs through a lariat structure (Fig. 1.2) (reviewed 
in Padgett, Grabowski et al. 1986).  First, the 2’OH of the invariant ‘A’ nucleotide 
of the branch point performs nucleophilic attack on the phosphate bond upstream 
of the invariant ‘G’ nucleotide of the 5’ splice site separating the first exon/intron 
junction.  The upstream exon continues to be linear while the downstream intron 
forms a lariat structure where the newly formed terminus at the 5’ end of the 
intron is linked by a 5’-2’ bond between its invariant ‘G’ nucleotide of the initial 5’ 
splice donor site and the 2’ position of an invariant ‘A’ nucleotide in the branch 
point sequence.  Next, the 3’ splice site undergoes nucleophilic attack by the free 
OH of the upstream exon separating the 3’ intron/exon junction.  The intronic 
lariat is debranched at the branch point and readily degraded.  The chemical 
reactions that occur at the splice sites and branch point are trans-esterification  
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Exon 1 Exon 2Intron 1
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C.
Figure 1.2. Transesterification steps and the intronic lariat intermediate 
in pre-mRNA splicing.   
 
Intron removal and exon joining in cis splicing occurs via two 
transesterification steps and an intronic lariat structure.  A) Representative 
pre-mRNA sequence containing 2 exons and 1 intron.  The 2’OH group of the 
invariant adenine nucleotide in the intronic branch point attacks the phosphate 
group at the exon/intron junction of the 5’ splice site.  B)  The lariat 
intermediate is formed.  The resulting free 2’OH group of exon 1 performs 
nucleophilic attack on the phosphate group at the intron/exon junction of the 3’ 
splice site.  C)  Intron sequence including lariat intermediate is released and 
degraded; exons 1 and 2 are joined.  
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reactions (Fig. 1.2).  In the original pre-mRNA structure there were two 5’-3’ 
bonds at the intron-exon junctions; these are exchanged for a 5’-2’ bond between 
the 5’ end of the intron and the branch point and a 5’-3’ bond linking the two 
exons. 
Stages of spliceosome formation 
The process of splicing is accomplished by a large macromolecular 
complex in the nucleus called the spliceosome.  The spliceosome is a large 50-
60S structure that rivals a ribosomal subunit in size; it is composed of several 
hundreds of proteins and five snRNPs that come together and interact in stages 
in every splicing reaction (Rappsilber, Ryder et al. 2002).  The major splicing 
components and steps are illustrated in Figure 1.3 and described here briefly, 
however significantly more can complex as more than 300 protein components 
have been identified (reviewed in Jurica and Moore 2003). The first stage called 
the E, or early presplicing, complex is sometimes referred to as the commitment 
complex since the pre-mRNA is first selected for splicing.  Here, the U1 snRNP 
along with the ASF/SF2 SR protein base pairs with the 5’ splice donor site 
(Jamison, Pasman et al. 1995) and the branch point binding protein (BBP) binds 
at the branch point sequence (Berglund, Chua et al. 1997).  U1 recognizes the 5’ 
splice site by simple base pairing between the 5’ end of the U1 snRNA and the 
sequence at the intron/exon boundary and this recognition does not require ATP 
(Lerner, Boyle et al. 1980; Rogers and Wall 1980; Zhuang and Weiner 1986).  A 
specific pyrimidine tract downstream of the branch point is then bound by U2 
associated factor (U2AF) (Moore 2000).  The polypyrimidine tract is highly  
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Figure 1.3.  Major steps of spliceosome formation.   
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Figure 1.3.  Major steps of spliceosome formation.   
 
A representative pre-mRNA sequence including two exons and one intron 
goes through the major stages of spliceosome formation.  Stages include 
the E complex (also termed the commitment complex), A, B1, B2, C1, and 
C2 complexes.  Addition, positioning, and removal of splicing factors 
including snRNPs and SR proteins guide spliceosome assembly through 
each stage and facilitate the joining of exons and removal of intron 
sequence (see Chapter 1 for a detailed explanation).  
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conserved and is necessary for spliceosome assembly (Ruskin and Green 1985; 
Green 1986; Barabino, Blencowe et al. 1990).  These two previous steps are 
required for the recognition of the branch point by U2 snRNP (Ruskin, Zamore et 
al. 1988); U2 snRNA binds complementary sequence in the branch point while 
other proteins in the U2 snRNP recognize RNA upstream of the branch point 
(Black, Chabot et al. 1985; Chabot and Steitz 1987).  When U2 snRNP joins the 
action, ATP is required, and the E complex becomes the A presplicing complex.  
The B1 splicing complex is where the complete spliceosome containing the U5 
and U4/U6 snRNPs is first identified.  The U5 snRNP joins the spliceosome with 
the aid of an intron binding protein after U1 and U2 bind to the pre-mRNA 
(Grabowski and Sharp 1986; Bindereif and Green 1987; Konarska and Sharp 
1987).  The U5/U4/U6 pre-formed triple snRNP binds both the 5’ splice site and 
the U2 snRNP with the aid of SR proteins (Roscigno and Garcia-Blanco 1995).  
Here is where the previously described lariat structure starts to take shape.  In 
the B2 complex, U1 is released from the 5’ splice site in order to position the 5’ 
splice site and the U6 snRNP.  In the C1 complex, ATP is required to release U4 
in order for to sequester U6 for binding to U2 (Lamond, Konarska et al. 1988).  
The U6/U2 complex binds the RNA hairpin structure to perform the trans-
esterification reactions where the 5’ splice site is cleaved and the lariat 
intermediate is fully formed.  The final C2 complex also requires ATP; the U5 
snRNP of the U2/U6/U5 complex binds the 3’ splice site which is then cleaved 
(Chiara, Palandjian et al. 1997).  The two exons are then joined and the final 
mRNA sequence is defined.  
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II. Alternative Splicing 
Since the discovery of DNA and gene structure in the middle of the 20th 
century, it was assumed widely that to achieve the phenotypic diversity seen in 
mammals and specifically humans, hundreds of thousands of genes would be 
required.  Only recently with the sequencing of the human genome have 
researchers determined that only about 30,000 genes or even less make up our 
entire genome (Lander, Linton et al. 2001; Venter, Adams et al. 2001). Discovery 
of the number of different protein products that can be obtained from a single 
gene by alternative pre-mRNA splicing and other processes helps to resolve the 
issue of small gene number and large protein diversity.  Several post-
transcriptional processes, including alternative splicing, increase protein diversity 
without the need for increasing gene number; alternative splicing is the best 
example of a mechanism that exposes the fallacy of the ‘one gene-one 
polypeptide’ theory in eukaryotes.   
Alternative splicing is an essential, biological process that can regulate 
gene expression in higher eukaryotes and contributes greatly to the complexity of 
the proteome by generating multiple protein isoforms.  Alternative splicing of 
eukaryotic pre-mRNA occurs when exonic or intronic sequences are selected to 
be either removed or retained, respectively, in mature mRNA.  Our 
understanding of splice site selection in alternative splicing is limited.  There is 
evidence that alternatively spliced introns have suboptimal splicing elements 
(Roca, Sachidanandam et al. 2003) that are poorly recognized by snRNPs and 
other splicing factors.  
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Previously, alternative splicing was thought to be a minor process 
occurring in only about 5% of human genes (Sharp 1994).  By recent estimates 
using bioinformatics analysis, DNA microarrays and protein sequence data, the 
primary transcripts of approximately 59% to 74% of human genes are subject to 
alternative splicing, generating from two to several thousand different mRNA 
isoforms for each gene (Hanke, Brett et al. 1999; Croft, Schandorff et al. 2000; 
Lander, Linton et al. 2001; Johnson, Castle et al. 2003).  Using a subset of genes 
on different chromosomes, the average number of alternatively spliced products 
per gene is estimated to be between 1.3 and 3.2 (Lander, Linton et al. 2001), but 
some genes including the human neurexin 3, giant muscle protein titin, calcium-
activated potassium channels, and the Drosophila Down syndrome cell adhesion 
molecule (DSCAM) gene can achieve potentially thousands to tens of thousands 
of different mRNAs (Ushkaryov, Petrenko et al. 1992; Schmucker, Clemens et al. 
2000; Bang, Centner et al. 2001; Strehler and Zacharias 2001).  This makes it 
easy to understand how the alternative splicing process is one of the most 
important mechanisms that lead to protein diversity since the number of different 
protein products from a single gene can be larger than the total number of genes 
in an entire genome. 
Regarding mRNA sequence, consequences of alternative splicing include 
complete or incomplete exon removal, partial or total intron retention and mutual 
exclusion of two different exons (Fig. 1.4).  Since protein domains tend to migrate 
with exon sequence throughout chromosomal rearrangements, the complete 
removal of an exon by alternative splicing will usually delete a specific motif or  
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Pre-mRNA
Complete Exon exclusion
1 3 4
431 421
Mutually excluded exons
2 31 4
‘Normal’ splicing 
Partial intron inclusion
1 32 4
Partial exon exclusion
21 3 4
mRNA
2 31 4
A.
B.
Figure 1.4. Multiple outcomes of alternative splicing.   
 
A) A representative pre-mRNA sequence containing 4 exons and 3 introns.  
B) Alternative splicing of the pre-mRNA is able to produce several different 
types of mRNA transcripts. 
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domain from the final protein product.  Commonly, protein domains that control 
membrane insertion are added or excluded by alternative splicing.  This is a 
powerful method of protein modification since protein localization is such an 
important part of determining enzymatic, signaling and structural function.  
Examples of this type of regulation by alternative splicing include cyclo-
oxygenase, Fas, Growth hormone receptor, Interleukin-2 and -4 receptors, 
Prostate specific membrane antigen and Vascular endothelial growth factor-I 
(Rosenfeld 1994; Cascino, Fiucci et al. 1995; Su, Huang et al. 1995; Blum, Wolf 
et al. 1996; Horiuchi, Koyanagi et al. 1997; Shibuya 2001; Chandrasekharan, Dai 
et al. 2002).   Mutual exclusion of exons can lead to tissue specific protein types 
or simply exchange of one protein domain type for another.   
By pure probability, almost two-thirds of alternative splicing events will 
change the reading frame of the mRNA sequence.  This is by far the potentially 
most devastating type of alteration since it usually produces an early stop codon 
and thus a truncated protein.  In many cases, early stop codons can initiate 
mRNA degradation by nonsense mediated decay (NMD); it has been estimated 
that about 18% to 25% of mRNA transcripts will be degraded by NMD due to the 
use of alternate sequence after alternative splicing (Lewis, Green et al. 2003).  
However, a change in reading frame also may cause the most significant 
alteration of protein sequence achieved by alternative splicing and produce a 
truly novel protein sequence.  Alternative splicing also is able to increase or 
decrease the level of protein expression by altering poly-adenylation signals, 
producing unstable mRNAs or altering tissue specific spliced product expression.   
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A. Alternative Splicing in Disease 
Mutations in either alternatively or constitutively spliced genes, or in genes 
coding or controlling the components of the splicing machinery can alter splicing, 
frequently leading to human disease.  Annotated database surveys show that up 
to 50% of point mutations contributing to genetic diseases either damage or 
modify splice sites, branch points, polypyrimidine tracts and/or enhancer 
elements involved in splicing and, therefore, result in aberrant splicing of pre-
mRNA and about 15% of all genetic disease mutations affect pre-mRNA splicing 
(Krawczak, Reiss et al. 1992; Cooper and Mattox 1997; Cartegni, Chew et al. 
2002).  Mutations in binding sites for SR proteins including SF2/ASF, SRp40 and 
SRp55 have also been associated with disease when found in genes such as 
BRCA1 (Liu, Cartegni et al. 2001) and SMN (Cartegni and Krainer 2002). 
Disease causing alteration of splicing pathways is frequently due not to 
mutations present in pre-mRNA, but to a change in the expression of factors that 
influence alternative splicing.  One example involves the CD44 family of 
membrane glycoproteins, which function as cell adhesion molecules.  The CD44 
gene is complex, and is comprised of 20 exons. Alternative splicing of 10 variable 
exons gives rise to a diverse range of CD44 protein isoforms.  Some CD44 splice 
variants are associated with tumor metastasis and may be used in cancer 
diagnosis.  A mutational analysis of one particular variable exon, v5, revealed a 
composite structure of enhancer and silencer elements regulated by signal 
transduction pathways (Woerfel and Bindereif 2001).   
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A clear cause and effect relationship between the modulation of splicing 
and cancer is exemplified by bcl-x, a gene involved in the apoptotic pathway 
where over-expression of a longer splice variant, bcl-xL, of this gene is 
associated with advanced, aggressive cancers (Reed 1998).  Other alternatively 
spliced genes associated with human cancer have been reviewed elsewhere 
(Mercatante, Sazani et al. 2001) and examples of alternatively spliced genes 
implicated in other diseases are described later. 
B. Antisense Modulation of Alternative Splicing 
Antisense modification of gene expression exists in nature and also can 
be accomplished by synthetic small molecules and oligonucleotides.  A 
comprehensive volume (Crooke 2001) and more recent reviews cover antisense 
technology (Dean and Bennett 2003; Kurreck 2003).  It is noteworthy that even 
the newly discovered phenomenon of RNA interference (RNAi) ultimately is 
dependent on small interfering RNAs (siRNA) that interact with the target RNA 
via an antisense mechanism.  In most cases the antisense effects lead to down-
regulation of gene expression. As will be discussed below, using antisense 
molecules for modification of the complex mechanisms of pre-mRNA splicing 
allows not only down-regulation but also up-regulation and modulation of 
expression of targeted genes.  This unique ability makes the application of 
antisense oligonucleotides particularly attractive, in view of the fact that a 
majority of genes generate alternatively spliced pre-mRNA.  The next section 
focuses on antisense oligonucleotide targeting of previously discussed splicing 
elements to significantly alter the splicing patterns.  This concept has clinical 
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relevance, since many diseases result from misguided, alternative or aberrant 
splicing (reviewed in Sazani and Kole 2003; Vacek, Sazani et al. 2003). 
III. Splice switching oligonucleotides 
 Oligonucleotide based mechanisms have long been used for manipulation 
of intracellular RNAs and even DNAs in vitro and in vivo (reviewed in Crooke 
2004; Aboul-Fadl 2005).  Sequence-specific base pairing of engineered 
molecules with native cellular sequences has been able to sterically block gene 
expression at different stages including: transcription initiation through a triplex 
mechanism, spliceosome recognition, translation, and by recruiting proofreading 
machinery; all of these approaches have been used for the purpose of 
therapeutics and/or disease research.  In most cases, short DNA and DNA-
based nucleic acid sequences, or oligonucleotides, are the molecules of choice 
for performing antisense research, although (as will be described later) others 
including snRNAs and small organic molecules also have been useful.  
Moreover, antisense oligonucleotides are used most widely to target mRNAs for 
degradation by the RNAse H enzyme, presumably in the cytoplasm (reviewed in 
Nesterova and Cho-Chung 2004).  RNase H has the ability to degrade any RNA 
sequence included in a DNA/RNA duplex, an advantageous behavior when trying 
to diminish RNA levels.  This downregulation of gene expression has been 
almost universally effective in tested transcripts and particularly useful in bcl-2, 
protein kinase C alpha (pkCα), and intercellular adhesion molecule 1 (ICAM-1) 
research (Dean and McKay 1994; Gutierrez-Puente, Zapata-Benavides et al. 
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2002), even producing Vitravene®, a successfully approved therapeutic for AIDS 
related cytomegalovirus retinitis (de Smet, Meenken et al. 1999). 
 For some research applications using antisense technology, including 
alternative pre-mRNA splicing manipulation, degradation of transcripts by RNase 
H is not desired; the array of modified antisense oligonucleotides with specialized 
properties (including RNase H resistance) has grown and become increasingly 
more complex in chemistry to adapt to specific needs.  These structural 
modifications have produced second generation antisense oligonucleotides with 
improved sequence specificity, binding capability, cellular and nuclear targeting 
and decreased toxicity (reviewed in Altmann, Fabbro et al. 1996; Monia 1997).  
For the purpose of targeting pre-mRNA sequences to interfere with splicing 
processes, it is desirable for antisense oligonucleotides to (1) reach the nuclear 
space where splicing takes place, (2) not recruit RNase H degradation, (3) have 
high binding affinity to targeted sequence, and (4) target known splicing elements 
in order to produce a predictable splicing pattern. 
This laboratory has pioneered the use of antisense oligonucleotides 
targeted to pre-mRNA sequence in order to influence alternative splicing 
patterns.  This specific use of short antisense sequences, termed splice-
switching oligonucleotides (SSOs), has been successful in the modulation of 
mRNA level of several different transcripts including cftr, β-globin, bcl-x, and 
recently prostate specific membrane antigen (PSMA) (Sierakowska, Sambade et 
al. 1996; Friedman, Kole et al. 1999; Mercatante, Bortner et al. 2001), Williams 
and Kole, in press). 
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A. Chemistry 
To be effective in modification of splicing, the oligonucleotides must bind 
to pre-mRNA without inducing degradation of the RNA duplexed with the 
oligonucleotide by RNase H, a ubiquitous enzyme.  Thus, splice switching 
oligonucleotides include modifications such as 2’-O-methyl- and 2’-O-
methoxyethyl- (MOE) substitutions of ribose, methylphosphonate 
oligodeoxynucleotides, morpholino, and peptide nucleic acid (PNA) (reviewed in 
(Sazani and Kole 2003).   
2’ modifications replacing the 2’OH group in RNA based oligonucleotides 
alone can grant RNase H resistance.  2’-O-methyl- and 2’-O-methoxyethyl- 
chemical modifications were shown to also have greater target affinity and 
nuclease resistance (Manoharan 1999).  A 2’-O-aminopropyl sugar conformation 
involves an extended amine terminated – three carbon group bound to the 2’ 
oxygen.  This modification neutralizes the phosphate derived overall negative 
charge of the oligonucleotide molecule by introducing one positive charge from 
the amine group per sugar.  2’-O- aminopropyl substitutions improve cellular 
uptake properties compared to unmodified oligonucleotides because of its 
zwitterionic properties (Teplova, Wallace et al. 1999).  Another available 2’ 
modification includes a locked or bridged ribose conformation where the 4’ ribose 
position also is involved; an oxygen molecule bound at the 2’ carbon is linked to 
the 4’ carbon by a methylene group.  This ribose conformation grants RNase H 
resistance and greater binding affinity (Orum and Wengel 2001).   
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Morpholino oligonucleotides further deviate from standard nucleic acid 
structure by changing both the sugar and phosphate chemistries.  Here, the five 
member ribose ring is substituted with a six member morpholino ring containing 
four carbons, one nitrogen and one oxygen.  The ribose monomers are linked by 
a phosphordiamidate group instead of a phosphate group.  These backbone 
alterations remove all positive and negative charges making morpholinos neutral 
molecules that more easily cross cellular membranes without the aid of cellular 
delivery agents often used by charged oligonucleotides.  Morpholino 
oligonucleotides benefit from the same advantages granted other modified 
oligonucleotides, including RNase H and nuclease resistance and high binding 
affinity (Stein, Foster et al. 1997; Summerton 1999). 
The peptide nucleic acid (PNA) chemically modified oligomers differ 
greatly from what is normally recognized as nucleic acid.  There is no sugar ring 
or phosphate linkage; in their place, bases are attached and appropriately 
spaced by oligoglycine – like molecules.  PNA oligomers also have no backbone 
charge and, due to their engineered chemical positioning of bases, have a high 
sequence binding affinity (Nielsen, Egholm et al. 1991; Hanvey, Peffer et al. 
1992).  It is also obvious as to why PNAs are not recognized by cellular 
nucleases or RNase H.   
Oligonucleotide modifications that involve base chemistry are not widely 
used, but have been shown to be beneficial in some antisense studies.  The C-5 
propynyl cytosine modification amplified antisense activity in concert with 
phosphorothioate backbone linkages, where the oxygen with a double bond to 
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the phosphorous atom in a normal phosphate group is replaced by a sulfur atom.  
Note that phosphorothioate linkages can replace phosphates in combination with 
other backbone and base modifications to reduce nuclease recognition (Eckstein 
2000).  Two other cytosine base chemical modifications include heterocyclic 
phenoxazine and G-clamp (Moulds, Lewis et al. 1995; Raviprakash, Liu et al. 
1995; Flanagan, Kothavale et al. 1996) that both give higher target binding 
affinities. 
B. Delivery 
Since splicing is a nuclear process, the oligonucleotides must have the 
ability to enter or be delivered efficiently to the cell nucleus.  In cell culture, 
several different cationic carriers enhanced uptake of negatively charged 
oligonucleotides with sugar-phosphate backbones to the nuclei and led to a shift 
in splicing of several targets (reviewed in (Kole and Sazani 2001). Uncharged 
splice switching oligonucleotides such as morpholinos or PNAs cannot be 
delivered to cells by cationic carriers. Nevertheless, splice switching was 
observed in cultured HeLa and in erythroid cells from thalassemic patients when 
the oligonucleotides entered the cells subsequent to mechanical disruption of the 
cell membrane using a scrape-loading or syringe-loading technique (Lacerra, 
Sierakowska et al. 2000; Sazani, Kang et al. 2001; Suwanmanee, Sierakowska 
et al. 2002).  Splice switching by morpholino and PNA oligonucleotides, but not 
by their negatively charged counterparts, also was observed, albeit at high 
concentrations, upon free uptake into these cells (Sazani, Kang et al. 2001; 
Suwanmanee, Sierakowska et al. 2002).  Splice switching has also been 
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achieved in cell culture using viral vectors for stable and prolonged delivery of 
antisense RNA (Vacek, Ma et al. 2003) or by oligonucleotide conjugation with Tat 
or antennaepedia cell-penetrating peptides (Astriab-Fisher, Sergueev et al. 2002; 
Moulton, Hase et al. 2003).  
C. Readout 
Although antisense oligonucleotides are beginning to be accepted as 
therapeutics and are undergoing numerous clinical trials 
(http://www.clinicaltrials.gov/), their delivery and cellular uptake still need 
improvement. An assay that provides a clear, sequence specific read-out would 
be very useful in further investigations of the improved oligonucleotides. 
Modification of splicing by SSOs, which results in generation of a new splice 
variant on a null or low background, provides such an assay.  This laboratory has 
developed reporter splicing assays in cell culture and in a transgenic mouse 
model, which allow determination of the levels of splice switching by any 
antisense molecule (Gemignani, Landi et al. 2001; Sazani, Vacek et al. 2002).  
One assay was devised and exploited to analyze in cell culture and in vivo the 
antisense effects of several novel oligonucleotide chemistries.  The assay utilizes 
an enhanced green fluorescent protein (EGFP), the coding sequence of which is 
interrupted by a defective intron from human β-globin gene. The intron carries a 
thalassemic C- to T- mutation at position 654 that creates an aberrant 5’ splice 
site and activates an additional 3’ splice site upstream. The resultant aberrant 
splicing prevents production of correct EGFP mRNA and protein (Sazani, Kang 
et al. 2001). Antisense molecules targeted to the aberrant splice site restore 
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correct splicing, leading to uninterrupted EGFP mRNA properly translating full 
length EGFP with detectable fluorescence.  For in vitro and in vivo testing, this 
construct was either stably transfected into HeLa cells or expressed in a 
transgenic mouse model.  In the absence of oligonucleotide treatment, virtually 
no EGFP mRNA was present, and very little or no background fluorescence was 
detected in cultured cells or mouse tissues. This system tests sequence specific 
antisense activity; the generated fluorescence is directly proportional to the 
effectiveness of the antisense molecules in splice shifting; the level of 
fluorescence in analyzed cells and tissues directly correlates with the 
oligonucleotides’ nuclear uptake and splice-shifting potential (Sazani, Kang et al. 
2001; Sazani, Gemignani et al. 2002).  The oligonucleotide-induced positive 
readout of EGFP fluorescence indicates that the active, in vivo injected 
oligonucleotides, distributed to different tissues, crossed the cell membranes, 
translocated to the nuclei where they blocked the aberrant splice site, interfered 
with the normal functioning of the spliceosome, and forced the splicing machinery 
to select an alternative splice site.  The results can be quantified at the mRNA or 
protein level and by fluorescence-activated cell sorting (FACS) analysis of 
cultured cells or microscopy of sectioned mouse tissue. The assay allows 
comparison of effectiveness of oligonucleotide analog chemistries, delivery 
agents and different delivery approaches.  
Using this assay, antisense properties of peptide nucleic acid (PNA), 
morpholino, 2’-O-methoxyethoxy (MOE) and 2’-O-methyl (OMe) were 
investigated. Interestingly, with ‘free uptake’ of the oligonucleotides into cultured 
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HeLa cells, with no special delivery methods or agents, antisense efficiency 
seemed to be related to a net backbone charge. The neutral PNA and 
morpholino analogs performed better than their negative counterparts (MOE and 
OMe).  The addition of four lysine residues to PNA analogs increased their 
efficacy presumably due to a positive charge conferred by the basic amino acids 
(Sazani et al., 2001).  Consistent with in vitro cell line data, the PNA-4-lysine 
chemistry out-performed all other oligonucleotides tested in vivo, exhibiting 
significant fluorescence in the liver, kidney, heart and lung tissues of the EGFP 
mouse.  Interestingly, only the PNAs induced significant EGFP fluorescence both 
in HeLa cells when delivered without adjuvants from the media (10 µM) or in vivo 
by I.P injection (50 mg/kg) in the EGFP mouse.  Unexpectedly, MOE treated 
animals also showed intense response to treatment with detectable fluorescence 
in several tissues; in contrast a neutral morpholino oligonucleotide analog 
induced significant fluorescence in HeLa cells but was only marginally effective in 
vivo showing little response in all tissues tested (Sazani et al., 2002b).  Lack of 
morpholino effects are likely a consequence of rapid renal clearance of such 
molecules (Agrawal et al., 1995).  2’-O-methyl-oligonucleotides were not tested in 
vivo in the transgenic model.  The tissues that showed the highest fluorescence 
were liver, kidney, lung, heart and small intestine (Sazani, Gemignani et al. 
2002).  Recently the EGFP-based splicing assay also was used for cell culture 
testing of oligonucleotide based modifications that increased binding of these 
compounds to their target. No effect on splice shifting was observed (Sazani et 
al., 2003).  An earlier version of the assay, based on luciferase read-out (Kang et 
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al., 1998), also was used to study morpholino oligonucleotides conjugated to 
peptides, some of which were found to improve cellular and nuclear uptake of the 
conjugates (Moulton et al., 2003).  
This stringent test of antisense activity can be used in investigations of 
different delivery agents and/or oligonucleotides with diverse chemistries. For 
example, the EGFP based splicing assay was used to test in cell culture the 
antisense effect of increased binding of the oligonucleotides to the target RNA. 
Surprisingly, base substitutions such as G-clamp, C-propynyl or phenaxazine in 
oligonucleotides with a MOE backbone had no effect when the oligonucleotides 
were freely taken up by the cells or delivered by the scrape-loading technique 
(Sazani et al., 2003c). Note that a similar lack of increased effect was observed 
in vivo when chimeric MOE oligonucleotides were derivatized with C-propynyl 
groups and used in RNase H dependent antisense downregulation assay (Shen 
et al., 2003).  
D. Other splice-switching techniques 
snRNAs 
Small nuclear RNAs that exist in the cell as RNA processing factors have 
been exploited for modification of splicing by replacing their authentic antisense 
sequences with those directed toward a specific splicing element in a targeted 
gene (reviewed in Vacek, Sazani et al. 2003).  RNA recognition sequences of the 
U1 and U7 snRNAs were modified to identify and bind to 3’ cryptic splice sites in 
the β-globin pre-mRNA.  These altered snRNAs used for splice switching were 
able to reduce aberrant β-globin splicing and induce correct splicing in vitro 
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(Gorman, Suter et al. 1998; Suter, Tomasini et al. 1999; Gorman, Mercatante et 
al. 2000).  Similarly, U7 snRNA targeted to splice sites around exon 23 of the 
dystrophin transcript was able to cause exon exclusion in wild type and 
immortalized mdx muscle tissue culture cells, and to rescue the production of 
functional dystrophin protein (Brun, Suter et al. 2003).  Delivery of splice 
switching snRNAs into the cell can be improved by placing them into viral vectors 
where long term, stable expression can be achieved (Vacek, Ma et al. 2003; Liu, 
Asparuhova et al. 2004).  U1, U2, and U7 snRNAs encoded in viral vectors also 
have been used to induce exon skipping in dystrophin pre-mRNA as described in 
more detail later. 
Trans-splicing 
Although most pre-mRNAs undergo cis-splicing to form mature mRNA, 
trans-splicing, whereby sequences from two independently transcribed pre-
mRNAs are spliced to form a composite mRNA, also exists. In two recent papers 
the latter process was exploited for therapeutic purposes.   In the spliceosome-
mediated RNA trans-splicing (SMaRT) technique a fragment of pre-mRNA, which 
carries exon sequences with correct reading frame of the targeted gene, is 
designed to base pair with the intron of a targeted pre-mRNA upstream of the 
exon with a disease causing mutation, such as 508 in the cystic fibrosis trans-
membrane conductance regulator (CFTR) gene.  The construct enhances trans-
splicing between the two molecules and suppresses cis-splicing of the target 
thereby replacing the defective exon with a correct one.  Recently, Liu et al. 
demonstrated that SMaRT corrected endogenous mutant CFTR pre-mRNA ex-
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vivo in airway epithelia from patients with cystic fibrosis and partially restored 
CFTR-mediated chloride transport.  The same construct was inserted in the 
adenoviral vector and shown to be effective in vivo in xenografts of human CF 
bronchial cells (Liu, Jiang et al. 2002).  SMaRT also has been used to repair pre-
mRNA of Factor VIII in a mouse model of hemophilia A. The levels of functional 
Factor VIII reached 12% of normal (Chao, Mansfield et al. 2003).  Note that in the 
cystic fibrosis model the trans-splicing molecules were injected directly into the 
xenograft while in the hemophilia model, large volumes were delivered by tail 
vein injections, exploiting hydrodynamic pressure to improve uptake of the 
construct (Budker, Zhang et al. 1996).  Thus, although the progress is very 
encouraging, this and other related technologies need to overcome the 
challenges of delivery of relatively large molecules.  
IV. Gene targets of splice switching 
A. β-globin 
β-Thalassemia is a blood disease resulting from reduced or absent 
production of functional β-globin, a subunit of hemoglobin. Severe cases of 
thalassemia, if untreated, result in early death. Current treatment consists of 
frequent transfusions combined with iron chelation therapy. Inability to produce 
hemoglobin is caused by mutations in the β-globin gene, affecting various stages 
of β-globin biosynthesis. While over 200 mutations lead to this disease, several 
common forms of thalassemia are due to mutations in β-globin gene introns that 
create alternative splice sites and lead to aberrant splicing of pre-mRNA. The 
result is inclusion of the intron fragment, which creates a nonsense codon in the 
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β-globin coding sequence, preventing translation of the protein (Olivieri 1999). 
This laboratory has used splice switching oligonucleotides to target aberrant 
splice sites and induce a shift from aberrant to correct splicing, restoring 
expression of hemoglobin. Sequence specific correction of splicing was achieved 
in model cell lines and subsequently by ex vivo treatment of erythroid progenitors 
cells from thalassemia patients (Vacek, Ma et al. 2003).  In these studies, the 
SSOs were delivered by cationic lipid delivery agents or by temporary, 
mechanical damage to cell membranes (Lacerra, Sierakowska et al. 2000).  Free 
uptake of SSOs by the cultured erythroid cells also was accomplished using 
oligonucleotides with a neutral, morpholino backbone.  High levels of correct 
RNA and hemoglobin expression were achieved after several days of treatment 
(Suwanmanee, Sierakowska et al. 2002; Suwanmanee, Sierakowska et al. 
2002). Like most other pharmacological agents, SSOs effects are relatively short 
term due to their degradation and excretion. Thus, the possibility of long-term 
repair of β-globin pre-mRNA also has been investigated. The sequence 
antisense to the aberrant splice sites in β-globin pre-mRNA was cloned into a U7 
snRNA gene, and the modified anti-β-globin U7 snRNA expressed from its own 
promoter served as a means to deliver antisense sequences to erythroid cell 
nuclei. Previous work relied on transfection of appropriate plasmids, but later the 
modified U7 gene was incorporated into lentiviral vectors. Treatment of cells, 
both model cell lines and thalassemic patients’ erythroid progenitors, resulted in 
significant upregulation of β-globin mRNA and functional protein expression. 
Although the level of expression was not as high as in the SSO treated cells, the 
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effects were permanent in the cell lines and lasted as long as the primary 
erythroid cells could be maintained in culture (Vacek, Ma et al. 2003). Antisense 
RNA delivery via lentiviral vectors is especially appealing in chronic diseases 
such as β-thalassemia that require lifelong correction of splicing. One advantage 
of RNA repair, especially for a gene that is as tightly developmentally controlled 
as β-globin is that the target gene is expressed in its natural environment and 
therefore cannot be over- or inappropriately expressed. As mentioned previously, 
RNA repair allows up-regulation or re-expression of a defective gene, a result 
that cannot be achieved by RNAi or standard antisense approaches. 
B. Dystrophin 
Exons, i.e. coding sequence mutations that disrupt the dystrophin reading 
frame lead to premature termination of protein synthesis, resulting in Duchenne 
muscular dystrophy (DMD).  In contrast, deletions that maintain the reading 
frame lead to the synthesis of a shorter, semi-functional dystrophin protein, 
resulting in the less severe Becker muscular dystrophy (BMD).  Therefore, 
skipping of the mutated exon may remove the offending mutation and restore the 
reading frame, converting DMD to a milder BMD phenotype.  Indeed, a series of 
recent papers showed restoration of dystrophin expression in the mdx mouse 
model of the disorder. In this model, exon 23 carries a mutation that introduces a 
stop codon.  Intramuscular injection of the 2’-O-methyl oligonucleotides 
complexed with Lipofectin targeted to exon 23 splice sites restored detectable 
dystrophin protein near the site of the injection (Mann, Honeyman et al. 2001).  
More recently, 2’-O-methyl oligonucleotides injected into the tibialis muscle in the 
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presence of the nonionic block polymer, F127, widely used in drug formulations, 
restored dystrophin expression to at least approximately 20% of normal.  
Importantly, the treatment measurably increased the strength of the injected 
muscle (Lu, Mann et al. 2003; Lu, Rabinowitz et al. 2005).  One notes that the 
volume of the oligonucleotide formulation (30 µl) was close to the volume of the 
injected muscle.  Thus, it seems possible that in addition to F127 a hydrodynamic 
pressure created in the muscle by the large amount of the injected liquid might 
have induced intracellular uptake of the oligonucleotides.  Similar results were 
obtained by intramuscular injection with morpholino oligonucleotides alone (Alter, 
Lou et al. 2006) or complexed with Lipofectine (Gebski, Mann et al. 2003).  Since 
morpholino oligonucleotides are uncharged Gebski et al. hybridized these 
molecules to negatively charged “leash” oligonucleotides. The leash concept was 
previously applied to morpholino oligonucleotides (Morcos 2001).  
Antisense RNAs encoded in viral vectors have also been used to induce 
exon skipping in human dystrophin pre-mRNA by replacing sequences in U1, U2 
and U7  snRNAs with sequences antisense to the 5’ and 3’ splice sites of 
dystrophin exon 51 (De Angelis, Sthandier et al. 2002).  These modified snRNA 
genes were then cloned into the 3’ LTR of the pBabe puro retroviral vector.  Viral 
particles were used to transduce muscle cells from a DMD patient having a 
deletion encompassing exons 48-50. Since this deletion created a premature 
termination codon in exon 51, skipping of this exon partially restored the reading 
frame of the gene and rescued dystrophin synthesis.  The most efficient skipping 
was obtained when both the 5’ and 3’ splice sites of exon 51 were targeted with 
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antisense molecules. Similarly to the work in mdx mouse these results indicate 
that restored expression of dystrophin, even carrying substantial deletions, may 
alleviate the symptoms in patients with DMD.  
C. Sma 
Spinal muscular atrophy (SMA), an inherited neurodegenerative disorder 
is caused by mutations in one of the survival of motor neuron genes (SMN1) 
even though a duplicated copy of the gene (SMN2) also exists.  SMN2 retains a 
correct open reading frame for SMN protein but its exon 7 is skipped, leading to 
expression of a nonfunctional gene product.  To reverse exon skipping 2’-O-
methyl oligonucleotides were targeted to the 3’ splice of the downstream exon 8, 
based on the assumption that blocking of that splice site will tilt the balance of 
splicing to favor inclusion of exon 7. Indeed, this was accomplished in model cell 
lines that stably express minigene constructs of SMN2  (Lim and Hertel 2001).  
Thus, this therapeutic strategy may be useful in counteracting the progression of 
SMA. Modulation of inclusion of SMN exon 7 also was accomplished in cell 
culture by 2’-O-methyl-oligonucleotides targeted to the newly discovered intronic 
splicing silencers and enhancers located, respectively upstream and downstream 
from exon 7 (Miyajima, Miyaso et al. 2002; Miyaso, Okumura et al. 2003). 
D. Tau 
The 5’ splice site of exon 10 of the tau gene is sequestered in a stem-loop 
structure and, therefore, this exon is to a large extent excluded from the mature 
Tau mRNA.  A mutation implicated in the frontotemporal dementia and 
Parkinsonism associated with chromosome 17 (FTDP-17) destabilizes the stem 
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and exposes the splice site, leading to inclusion of the exon. 2’-O-methyl 
phosphorothioate oligonucleotides, targeted either to the 3’ or the 5’ splice sites 
of tau exon 10, forced exon skipping and restored a proper ratio of the splice 
variants.  This effect was achieved by electroporation of the oligonucleotide into 
rat neuronal pheochromocytoma PC12 cells or AR42J pancreatic acinar cells.  In 
the latter cells, decreasing the levels of exon 10 containing protein, which 
includes a microtubule-binding domain, caused rearrangement of cytoskeletal-
structure, a potentially therapeutically favorable outcome (Kalbfuss, Mabon et al. 
2001).  
E. Bcl-x 
Bcl-x, like other members of the bcl-2 family of genes is involved in 
apoptosis. Its two primary splice forms, bcl-xL and bcl-xS, are generated by 
alternative splicing of bcl-x intron 2 (Cory and Adams 2002 and references 
quoted therein), via the use of a common 3’ splice site and two alternative 5’ 
splice sites. Bcl-xL, the longer splice variant, is anti-apoptotic. Moreover, high 
levels of bcl-xL have been correlated with resistance to chemotherapy (Liu, Page 
et al. 1999). The shorter variant, bcl-xS, which uses a 5’ splice site farther 
upstream from the 3’ splice site than bcl-xL, has been shown to have pro-
apoptotic properties (Minn, Boise et al. 1996). SSOs targeted against the bcl-xL 
5’ splice site were shown to shift splicing towards production of bcl-xS in the lung 
epithelial cancer cell line A549 (Taylor, Zhang et al. 1999). Although the splice 
shift alone was insufficient to induce apoptosis, it enhanced the apoptotic effects 
of chemotherapeutics administered with the oligonucleotide. In contrast, prostate 
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cancer PC3 cells were sensitive to SSO treatment in the absence of anti-cancer 
drugs (Mercatante, Bortner et al. 2001). The cell sensitivity was correlated with 
the level of bcl-x expression or more accurately with the absolute amounts of bcl-
xS generated by the anti-bcl-xL SSO. In addition, the SSO treatment sensitized 
the cells to chemotherapeutics and radiation and interestingly, led to cell death in 
a cell line that was resistant to doxorubicin, a common anti-cancer drug 
(Mercatante, Mohler et al. 2002).  Bcl-x is a particularly useful target for SSOs 
because the two splice variants have opposing functions. Thus, a shift in splicing 
simultaneously reduces the level of anti apoptotic bcl-xL and increases the level 
of pro-apoptotic bcl-xL, enhancing the effects of SSOs. The results also suggest 
that expression of possibly thousands of alternatively spliced genes can be 
manipulated by SSOs either as research tools in investigations of gene function, 
or possibly as drugs when targeted to disease associated genes, following the 
example of bcl-x (Mercatante and Kole 2000).  
V. Prostate Cancer 
 Prostate cancer is the primary malignancy and the second leading cause 
of cancer deaths in men behind lung cancer (Jemal, Murray et al. 2005).  
Fortunately, most men who get prostate cancer during their lifetime will die with 
the disease instead of from it.  However, although prostate cancers are normally 
slow growing and progressing, if not completely eradicated, they will eventually 
become androgen independent, causing a high mortality rate in men with 
uncontrolled prostate cancer.  Management of those diagnosed with prostate 
cancer can be a challenging balance between treatment and quality of life (Wei, 
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Dunn et al. 2002).  To add to the dilemma of how to treat prostate cancer, new 
diagnostic, screening and imaging techniques are now able to detect cancers at 
a much earlier stage than previous technologies; it is not yet known if these 
advances actually decrease the morbidity and/or mortality rates of the disease.  
Several groups have been involved in the research on this topic (i.e. risk 
assessment and decision making in treatment of prostate cancer); two of the 
largest research groups are the Cancer of the Prostate Strategic Urologic 
Research Endeavor (CaPSURE) and the Department of Defense Center for 
Prostate Disease Research (CPDR) (reviewed in Cooperberg, Moul et al. 2005).  
Their studies along with others have been crucial in mapping the progression of 
prostate cancer.  It has been determined that for the first 10 to 15 years many 
prostate cancers are usually idle and slow to progress, but beyond 15 years, the 
mortality rate triples (Johansson, Andren et al. 2004).  Since the overdiagnosis 
and very early diagnosis of prostate cancer may not necessarily benefit patients, 
current protocol is to identify men that are at a higher risk for aggressive cancers; 
noted risk factors include a family history of prostate cancer and ethnic 
background, primarily having an African American ethnicity (Reddy, Shapiro et al. 
2003; Rebbeck 2005).  There is conflicting evidence as to whether obesity is an 
important risk factor (Giovannucci, Rimm et al. 2003; Amling 2004; Amling, 
Riffenburgh et al. 2004; Freedland, Aronson et al. 2004).  
A. Treatment of Prostate Cancer 
Due to the above problems with effective treatment of prostate cancer, 
current treatments are moving toward the approach of ‘active surveillance’ after 
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prostate cancer diagnosis instead of ‘watchful waiting’.  The difference in these 
approaches is the level of monitoring and the expectation of a more aggressive 
treatment when the disease begins to progress.  Localized prostate tumors are 
most often treated with radiation therapy or surgery while refractory or recurrent 
disease is treated with hormonal therapy. The Prostate Cancer Outcomes Study 
between 1994 and 1995 determined that 47% of patients received a 
prostatectomy, 23% received radiotherapy, 11% received androgen deprivation 
therapy and 19% received observation only (Harlan, Potosky et al. 2001).  A 
more recent estimate by the CaPSURE study found only 5.5% of patients 
electing to use observation only (Harlan, Cooperberg et al. 2003).   
B. Protein markers of prostate cancer 
 
Biomarkers are important for the study, diagnosis, detection, prediction 
and possibly treatment of cancer, and prostate cancer is no exception.  Useful 
molecular biomarkers of prostate cancer must be able to accurately measure 
cancer stage, progression and prognosis.  The search for the perfect prostate 
cancer predictor is still going strong because there is still no one biomarker that 
can alone differentiate between benign and malignant disease.  Efficacy of 
markers is measured by their ability to predict accepted measures of prostate 
cancer, including: Gleason score and clinical/pathological disease stage 
(Bostwick, Grignon et al. 2000; Quinn, Henshall et al. 2001).  To be a useful 
prostate cancer marker for potential immunotherapy, Sbulke et al. suggest a few 
prerequisites: the biomarker must be found predominantly in the prostate, be 
highly expressed in all prostate disease states, have a cell surface presentation,  
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Table 1.1  Biomarkers of prostate cancer: PAP, PSA, PSMA 
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but not be secreted, and have some enzymatic or signaling activity.  One review 
by Tricoli et al. lists and describes the cellular localization, biochemical function, 
and cellular function of several potential prostate cancer markers including the 
three most studied prostate cancer markers, prostatic acid phosphatase (PAP), 
prostate specific antigen (PSA), and prostate specific membrane antigen (PSMA) 
(Tricoli, Schoenfeldt et al. 2004).  Here, I will describe PAP and PSA, two 
historically popular prostate cancer markers the latter of which has become 
almost synonymous with assessing prostate cancer risk.  The PSMA biomarker 
will be discussed later in great detail. 
PAP 
PAP levels were first identified and linked to the prostate in 1935 
(Kutscher and Wolbergs 1935).  High levels of PAP in serum then became 
associated with prostate cancer and its metastases, making it the first verified 
prostate cancer marker (Gutman, Sproul et al. 1936; Gutman and Gutman 1938).  
Serum levels of PAP declined after antiandrogen therapy, but then rebounded 
after disease resurgence (Huggins and Hodges 1941; Schacht, Garnett et al. 
1984).  Analysis of PAP levels was successful in identifying men with advanced 
metastatic disease, but failed to detect cancer in men with primary tumors and 
early stage disease (Sullivan, Gutman et al. 1942; Nesbit and Baum 1951).  PAP 
did not become widely used as a diagnostic measure of cancer because its 
relatively high limits of detection made it undesirable; there was a need to identify 
malignancy earlier when the cancer is more likely to be cured. 
PSA 
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PSA was first found in serum from patients with prostate cancer in 1980 
(Papsidero, Wang et al. 1980), but had been previously identified in 1971 as a 
kallikrein-like serine protease (Hara, Koyanagi et al. 1971).  Its function was 
determined to be to proteolytically liquefy semen in the prostate (Dawson and 
Vogelzang 1994).  Originally, it was thought to be a prostate specific protein, but 
later studies confirmed its presence in other tissues including some female 
tissues (Papsidero, Wang et al. 1980; Myrtle, Klimley et al. 1986).  After a link 
was made between PSA and prostate cancer, serum limits of PSA in patients 
were established; a serum level of 4 ng/mL or less was defined as normal, 
whereas a higher serum level indicated the need for further evaluation and 
possible treatment (Myrtle, Klimley et al. 1986).  Over time, PSA became touted 
as the golden marker for prostate cancer diagnostics with large public campaigns 
to get all men over 50 years old to receive PSA blood tests on a regular basis.  
PSA was indeed effective in detection especially when combined with the use of 
digital rectal exams (Cooner, Mosley et al. 1990; Catalona, Smith et al. 1991; 
Brawer, Chetner et al. 1992; Labrie, Dupont et al. 1992), however, many became 
concerned with the sensitivity and specificity of the test (Wang and Kawaguchi 
1986; Guinan, Bhatti et al. 1987; Stamey, Yang et al. 1987; Stamey, Kabalin et 
al. 1989).  One problem involved the increase of PSA levels in the absence of 
cancer with conditions including benign prostate hyperplasia (BPH) and 
prostatitis.  False positives became the great blemish of PSA tests leading to 
unnecessary follow up techniques including biopsies.  Moreover, it was 
determined that 20 to 30% of men with test readings in the ‘normal’ range did 
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indeed have prostate cancer (Cooner, Mosley et al. 1990; Catalona, Smith et al. 
1991; Labrie, Dupont et al. 1992).  This level of inaccuracy in PSA screening due 
to false positives and false negatives make PSA highly criticized as a useful 
biomarker, although PSA remains the best and only United States Food and 
Drug Administration approved clinically available prostate cancer marker to date 
(FDA 1986; FDA 1994). 
VI. PSMA 
 The PSMA gene has become increasingly relevant to the varied fields of 
prostate and general cancer research, neuroscience, and folate/one-carbon 
metabolism due to its unique enzymatic functions and localization in different 
tissue types (reviewed in Heston 1997; Chang, Gaudin et al. 2000; Ghosh and 
Heston 2004).  PSMA may prove to be a more useful prostate cancer biomarker 
for imaging, detection and drug targeting than PSA or PAP since it is a 
membrane-bound protein on prostate cancer cells while the other two proteins 
are secreted.   
A. Discovery and identification of PSMA 
 
The PSMA protein was first identified in 1987 by Horoszewicz et al. during 
the production of monoclonal antibodies of spleen cells from Balb/c mice 
immunized with membranes taken from the LNCaP cell line they established in 
1978 (Horoszewicz, Kawinski et al. 1987).  That 7E11C-5.3 monoclonal antibody 
stained strongly LNCaP membranes, and also was highly specific for human 
primary prostate tissues, including benign prostate hyperplasia, prostate cancers 
and prostate metastases.  Israeli et al. later sequenced the PSMA polypeptide 
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after isolation of PSMA using the CYT-356 monoclonal antibody and peptide 
microsequencing by proteolytic cleavage and HPLC fractionation (Israeli, Powell 
et al. 1993).  Using degenerate primers followed by a cDNA hybridization probe, 
they were able to sequence and clone the entire PSMA cDNA.  The sequencing 
predicted a 2653 base pair cDNA and a 750 amino acid protein.  Rinker-
Schaeffer et al. determined PSMA was located on human chromosome 11 using 
southern blotting analysis of mouse or hamster/human somatic cell hybrids 
(Rinker-Schaeffer, Hawkins et al. 1995).  Two signals were detected, one 
localized to 11p and the other to 11q.  It was later realized that the 11p11-p12 
location encoded the PSMA gene and the 11q14 produced a PSMA-like gene 
presumably due to a duplication event (O'Keefe, Su et al. 1998).   
PSMA is highly expressed in LNCaP cells and to a lesser extent in CWR-
R1 cells, but not in the much used PC3 prostate cell line or DU-145 cells (Ghosh, 
Wang et al. 2005).  In normal prostate, PSMA is expressed in secretory epithelial 
cells and is upregulated with higher levels of expression in prostatic intraepithelial 
neoplasia (PIN) and prostate adenocarcinoma (Horoszewicz, Kawinski et al. 
1987; Bostwick, Pacelli et al. 1998).  Prostate cancers express PSMA at a higher 
level than benign prostate tissues and its expression has a positive correlation to 
cancer grade and stage (Lapidus, Tiffany et al. 2000; Ross, Sheehan et al. 
2003).   
Monoclonal antibodies specific to PSMA are currently being used in 
clinical settings.  The 7E11 mAb that was used to originally isolate PSMA has 
been improved by the linkage of 111Indium, 90Yttrium, and 131Iodine radiolabel to 
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detect tissues expressing PSMA in vivo (Kahn, Williams et al. 1994; Deb, Goris 
et al. 1996).  The 111Indium 7E11 modified mAb has been marketed by the 
Cytogen company (Princeton, NJ) as ProstaScint and was approved for detection 
of primary prostate cancer and metastasis by the Food and Drug Administration 
in 1997. 
Perhaps the most surprising and potentially important discovery in PSMA 
research is its localization and abundance in tumor neovasculature (Liu, Moy et 
al. 1997; Chang, Reuter et al. 1999; Chang, Reuter et al. 2001).  Therapeutic 
targeting of PSMA may be able to treat not just prostate cancers, but all types of 
tumors by destroying the route by which they receive nutrients.  Expression of 
PSMA also has been detected to a much lower extent in other tissues, including: 
brain, small intestine, kidney and muscle (Slusher, Robinson et al. 1990; Murphy, 
Ragde et al. 1995; Troyer, Beckett et al. 1995).   
B. Function of PSMA: NAALADase and FGCP 
 
NAALADase 
Just prior to the isolation and identification of PSMA, other groups were 
studying an enzyme that hydrolyzes the N-acetyl-aspartyl-glutamate (NAAG) 
dipeptide to N-acetyl aspartate (NAA) and glutamate in the brain (Robinson, 
Blakely et al. 1987).  This protein was isolated using polyclonal antisera and 
monoclonal antibodies to the NAAG carbodiimide linkage and was named N-
acetyl α-linked acidic dipeptidase (NAALADase).  NAA and glutamate are both 
important neurotransmitters in the brain; the latter being the principal excitatory 
neurotransmitter in the central nervous system (Hollmann and Heinemann 1994).  
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NAAG may act as a storage form of these two molecules and/or may also play its 
own role in signal transmission.  There is a linking between PSMA and neuronal 
signaling since both NAAG and NAALADase have been associated with several 
CNS disorders related to the dysfunction of glutamate neurotransmission, 
including schizophrenia (Tsai, Passani et al. 1995) and epilepsy (Meyerhoff, 
Carter et al. 1992; Meyerhoff, Carter et al. 1992).  It was hypothesized, and later 
confirmed by chromosome mapping, that NAALADase and PSMA were the same 
protein since PSMA also was able to hydrolyze NAAG (Fig. 1.5) and was 
sensitive to quisqualic acid, a potent inhibitor of NAALADase activity (Carter, 
Feldman et al. 1996). 
FGCP 
 Another intersection of two seemingly unrelated fields, folate nutrition and 
prostate cancer, attributed another function to the PSMA protein.  In the late 
1990s, genetic mapping determined that PSMA, NAALADase, and a third gene, 
folylpoly-γ-glutamate carboxypeptidase (FGCP) were all expressed from a single 
gene (Pinto, Suffoletto et al. 1996; Luthi-Carter, Barczak et al. 1998).  Note that 
the nomenclature committee of the International Union of Biochemistry and 
Molecular Biology has officially named the gene Glutamate Carboxypeptidase II 
(GCPII) (Barrett 1997), but in this work it is generally referred to as PSMA for 
simplicity.   
FGCP was first identified by Chandler et al. in 1986 (Chandler, Wang et al. 
1986).  Its function is to cleave terminal glutamate residues at the gamma linkage 
from poly-glutamated folates (Fig. 1.5).  The family of folates are B-vitamins  
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A. N-acetyl α-linked acidic dipeptidase (NAALADase)
B. Folylpoly-γ-glutamate carboxypeptidase (FGCP) 
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Figure 1.5. Enzymatic functions of PSMA.   
 
A) N-acetylated-a-linked-acidic-dipeptidase (NAALADase) function: the N-
acetyl-aspartyl-glutamate (NAAG) molecule is hydrolyzed to N-acetyl aspartate 
(NAA) and glutamate.  B) Folylpoly-γ-glutamate carboxypeptidase (FGCP) 
function (also termed Folate Hydrolase (FOLH1)) : terminal glutamate residues 
of poly-glutamyl folates (in this case di-glutamyl folate) are hydrolyzed. 
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essential in the mammalian diet, but not natively synthesized by mammalian 
cells.  Folate is required for several essential cellular processes including nucleic 
acid synthesis and methylation, the methionine cycle, and many others affected 
by the transfer of single carbon methyl groups (Eto and Krumdieck 1986; 
Jennings 1995).   
A low folate level causes hyperhomocystenemia due to deficiencies in 
metabolism of methionine (Selhub, Jacques et al. 1993; Clarke, Woodhouse et 
al. 1998).  Hyperhomocystenemia in turn leads to cardiovascular disease (Kang, 
Wong et al. 1987; Clarke, Daly et al. 1991; Boushey, Beresford et al. 1995; 
Danesh and Lewington 1998; Schnyder, Roffi et al. 2001; Klerk, Verhoef et al. 
2002), neural tube defects (Smithells, Sheppard et al. 1976; Czeizel and Dudas 
1992; Mills, McPartlin et al. 1995), anemia (Herbert 1967), and cognitive disease 
(Joosten, Lesaffre et al. 1997; Clarke, Smith et al. 1998; McCaddon, Davies et al. 
1998; Selhub, Bagley et al. 2000; Seshadri, Beiser et al. 2002).  Sauberlich et al. 
proposed that the folate bioavailability, or percentage of nutrient absorbed versus 
intake amount, of folate may be about 50% (Sauberlich, Kretsch et al. 1987).  
This is due mostly to the inability of cells to effectively transport polyglutamated 
folates across plasma membranes (Godwin and Rosenberg 1975; Halsted, 
Baugh et al. 1975; Halsted, Reisenauer et al. 1978; Bailey, Cerda et al. 1984; 
Keagy, Shane et al. 1988).   
The poly-glutamyl storage form of folate may account for upwards of two-
thirds of all ingested dietary folate (Melse-Boonstra, de Bree et al. 2002).  
Effective uptake of polyglutamyl folate requires hydrolysis of the glutamyl chain to 
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produce the monoglutamyl form of folate (Chandler, Harrison et al. 1991).  The 
extracellular portion of the FGCP protein performs these hydrolysis steps in the 
brush border of the small intestine and possibly the proximal tubule cells of the 
kidney (Liu, Moy et al. 1997) and allows for folate uptake by the reduced folate 
carrier).  A 1561 C>T polymorphism in exon 13 of FGCP that causes a H475Y 
amino acid substitution was associated with low serum folate and high plasma 
homocysteine levels in a population of Caucasian males (Devlin, Ling et al. 
2000).  In vitro, COS-7 cells expressing this polymorphism gave a 50% lower 
FGCP activity level than wild type FGCP expressing cells.  Although PSMA’s 
specific role as FGCP in the small intestine is well defined and understood, the 
reasons for its localization and function in prostate tissues remains unknown. 
It has not been determined whether PSMA’s folate hydrolase activity is 
functionally unique in humans or absolutely necessary for proper folate nutrition 
although other reports acknowledge that another protein must be able to 
hydrolyze NAAG (Bacich, Ramadan et al. 2002; Bzdega, Crowe et al. 2004).  
Bzdega et al. characterized an NAALADase expressed in cerebellar astrocytes of 
PSMA knockout mice which they called GCPIII (Bzdega, Crowe et al. 2004).  
There are a few hypotheses as to why PSMA is so highly expressed in 
normal and malignant prostate tissues compared to other tissues including brain 
and small intestine.  One idea is that PSMA helps maintain extracellular 
glutamate levels in the prostatic fluid compartment since glutamate is found in 
seminal fluid.  The prostate may be subject to an inherent folate deficiency that 
makes it prone to genetic instability and therefore cancer; expression of PSMA 
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may be one mechanism prostate cells use to increase intracellular and/or local 
folate levels.  It is also possible that PSMA localization on the prostate cell 
surface may itself play a role in malignant transformation by acting as a signaling 
or receptor molecule.  Finally, high expression of membrane bound PSMA in 
prostate tumors may ensure adequate folate levels in rapidly dividing cells by 
recycling stored folates that were sequestered in necrotic cells. 
PSMA knockouts 
To add to the complexity of the PSMA story, two different groups 
produced PSMA knockout mice with differing, almost opposite results.  Tsai et al. 
used a targeting vector that disrupted a 2.5 kb region containing exons 9 and 10 
with a 1.8 kb PGK-neomycin cassette.  PSMA null mutants were obtained in mice 
with a C57BL/6 background, but no live offspring were obtained.  They 
demonstrated the need for PSMA in normal development and that the absence of 
PSMA results in early embryonic death in mice (Tsai, Dunham et al. 2003).  
Conversely, Bacich et al. produced a PSMA knockout in mice with a chimeric 
129/SVJ on C57Bl/6 background also by insertion of a neomycin resistance 
cassette.  The 2.5 kb region of the insert was targeted to the Sac II site in exon I 
and the Hind III site in intron I.  Most of intron I was replaced by the PGK-
neomycin cassette and multiple stop codons were introduced in exons I and II.  
This group found evidence of an alternate route of NAAG hydrolysis.  They not 
only found no embryonic lethality, but describe “little detectable effect on the 
behavior and neurochemistry” of PSMA null mutant mice (Bacich, Ramadan et al. 
2002).   
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Reasons for the great divergence in results from these two groups are not 
readily apparent, but could be explained by a couple of differences in 
methodology.  The slight difference in mouse strain may have had an effect on 
viability; this cannot be ruled out since the total function of PSMA is not well 
defined.  Also, the method of producing the knockout mice is important; 
introducing stop codons in all three frames in exon I and the beginning of exon II 
may not be effective since splicing differences allow for the use of start codons in 
the second exon.  Considering the number of alternative splicing events that 
involve exon I and intron I, it is more desirable to use a gene knockout approach 
that targets another portion of the gene, as done by Tsai et al.  Nevertheless, 
both groups did verify their knockout by PCR genotyping, southern, and western 
blot analysis; explanation of their differing results remains elusive. 
C. Structure of PSMA 
Protein 
Several reports describe PSMA as a 100-110 kD protein composed of 750 
amino acids (Israeli, Powell et al. 1993).  Computational analysis followed by 
protein crystallization of its extracellular region verified the domain composition of 
PSMA (Davis, Bennett et al. 2005).  A short 19 amino acid intracellular region is 
located at the amino terminus and contains the first five amino acid residues, an 
MXXXL motif for protein internalization (Rajasekaran, Anilkumar et al. 2003).  
PSMA does internalize when bound to a ligand or specific antibodies which may 
implicate it as a receptor molecule (Liu, Moy et al. 1997; Anilkumar, Rajasekaran 
et al. 2003).  The cytoplasmic domain is followed by another small 24 amino acid 
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transmembrane domain.  This makes PSMA an unusual type II membrane 
protein in which the N-terminus is cytoplasmic while the C-terminus is 
extracellular.  PSMA’s protease domain is located at amino acids 56-116 and 
352-591 and is similar to the transferrin receptor and bacterial binuclear zinc 
exopeptidases’ protease domains (Rees, Lewis et al. 1983; Davis, Bennett et al. 
2005).  PSMA is also a metalloproteinase as it binds two zinc atoms in the 
enzymatic domain for functional activity (Rawlings and Barrett 1997).  The C-
terminal domain, amino acids 592 – 747, is called the helical domain and 
contains a dimerization motif.  Deletion of the final 15 PSMA residues was shown 
to abolish PSMA enzymatic activity (Barinka, Mlcochova et al. 2004), which is 
consistent with the observation that protein dimerization is necessary for PSMA 
function (Schulke, Varlamova et al. 2003).   PSMA also contains an apical 
protease associated domain (amino acids 117-351) that aids in making the 
substrate binding cavity and forming the dimer interface.  The overall structure of 
PSMA, i.e. one that includes a short cytoplasmic domain, one transmembrane 
domain, and a large extracellular enzymatic region is frequent among known 
membrane bound hydrolases (Kenny and Maroux 1982). 
 PSMA shows significant sequence homology to the transferrin receptor 
(TfrI).  Structurally, TfrI is also a type II protein and contains an N-terminal 
internalization domain made up of a YXRF amino acid sequence that allows 
internalization of its extracellular region when bound to iron-containing transferrin 
(Trowbridge and Collawn 1992).  TfrI also exists as a functional dimer and has an 
aminopeptidase domain using two zinc atoms at the active site (Schneider, 
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Sutherland et al. 1982; Mahadevan and Saldanha 1999), although TfrI’s 
peptidase function is thought to be vestigial.   
The PSMA protein contains 10 potential glycosylation sites that are 
important if not vital to its extracellular function; removal of asparagine binding 
sites partially or completely blocked PSMA’s NAALADase activity (Ghosh and 
Heston 2003).        
mRNA 
In normal prostate epithelium PSMA was determined to be not as highly 
expressed as the PSM’ splice variant, in which 266 nucleotides of PSMA exon 1 
is spliced out via an alternative 5’ splice site, is a predominant splice variant (Su, 
Huang et al. 1995).  PSM’ protein lacks the first 60 amino acids that wholly 
encompasses the transmembrane domain and, as a result, localizes to the 
cytoplasm (Grauer, Lawler et al. 1998).  Although PSM’ retains the folate 
hydrolase active site, similar to the domain isolated by Davis et. al (Davis, 
Bennett et al. 2005), its cytoplasmic enzymatic activity has been questioned 
(Ghosh, Wang et al. 2005) and the function of PSM’ is not known. In addition to 
PSMA and PSM’ other splice variants, PSMA-C, -D (Schmittgen, Teske et al. 
2003), PSMA∆6 (direct submission to NCBI #AF254357) and PSMA∆18 (Devlin, 
Ling et al. 2000) have been noted, but their expression level and function are 
largely unknown.  
PSMA C pre-mRNA is spliced from the 3’ splice site of intron 1 to an 
alternative 5' splice site located between those of PSMA and PSM' in exon 1.  As 
in PSM’ splicing, this pathway deletes the PSMA start codon; use of the AUG in 
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exon 2, predicts a protein identical to PSM'.  In PSMA-D, the PSM’ 5’ splice site 
is spliced to a cryptic 3’ splice site in intron 1, retaining a portion of intron 1 
sequence. The retained sequence includes a start codon, presumably adding 24 
extra amino acids to PSM-D protein.  The rest of its sequence is in frame and 
identical to corresponding amino acids in PSMA and PSM’.  
PSMA∆6 and PSMA∆18 variants have had little if any prior molecular 
characterization and analysis; this is the first study of these variants.  Sequence 
analysis of PSMA∆6 mRNA shows complete exclusion of exon 6 by the splicing 
machinery and predicts that removal of this exon would produce a frameshift in 
mRNA sequence. If translated and stable, the first 243 amino acids of the 
putative PSMA∆6 protein would coincide with those of PSMA followed by 30 
different C-terminal amino acids.  The resulting PSMA∆6 protein could be 
membrane-associated, but should be functionally inactive due to the lack of the 
enzymatic and dimerization domains.  In PSMA∆18, exon 18 is excluded leading 
to a putative 695 amino acid protein PSMA-like protein where the terminal 39 
amino acids, coded downstream of exon 17 are from the alternate reading frame.  
Although PSMA∆18 should contain the folate hydrolase active site it would lack 
the dimerization domain, which was found to be essential for enzymatic activity of 
PSMA or its extracellular domain (Schulke, Varlamova et al. 2003; Davis, 
Bennett et al. 2005). Thus, PSMA∆18 is expected to be inactive.  PSMA splice 
variants and their protein products are illustrated in Figure 1.6. 
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Figure 1.6.  Alternative splice variants of PSMA pre-mRNA.   
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Figure 1.6.  Alternative splice variants of PSMA pre-mRNA.   
 
A) Splice variants from alternative splicing involving PSMA’s first intron: full length 
PSMA contains all exon and no intron sequence; PSM’ utilizes an upstream 5’ splice 
site in exon 1 resulting in a protein that lacks the transmembrane domain; PSMA-C 
utilizes the same 5’ splice site as PSM’ and an alternate upstream 3’ splice site 
resulting in a protein identical to PSM’; PSMA-D utilizes the same 5’ splice site as 
PSM’ and PSMA-C, but includes a novel exon located in PSMA’s intron 1.  The first 
amino acids of the PSMA-D protein are not present in the other variants, but the rest 
of the protein is in frame.  B) Splice variants from alternative splicing involving exon 
exclusion: PSMA∆6 results from exon exclusion of PSMA’s exon 6, the protein is 
severerly truncated compared to PSMA with its final amino acids out of frame; 
PSMA∆18 results from exon exclusion of PSMA’s exon 18, its protein product is 
slightly truncated with the final amino acids out of frame. 
Grey boxes and circles indicate PSMA’s transmembrane domain, dashed lines show 
alternate splicing patterns, stars indicate location of the start codon, diamonds 
indicate location of the stop codon, checkered circles indicate an alternate reading 
frame.  
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CHAPTER 2 
Materials and Methods 
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Cell Culture and Tissue Samples 
Human prostate cancer cell lines, LNCaP-FGC and PC3, were obtained 
from the Lineberger Comprehensive Cancer Center Tissue Culture Facility 
(Chapel Hill, NC).  They were maintained in a humidified cell culture incubator 
with 5% CO2 at 37°C.  LNCaP cells were cultured in RPMI 1640 (Gibco), 
supplemented with 1 mM sodium pyruvate and 5% penicillin/ streptomycin 
solution (Gibco), and 10% fetal bovine serum (FBS) (Gemini).  PC3 cells were 
cultured in DMEM/F12 (Dulbecco’s Modified Eagle Medium, Gibco) 
supplemented with 1mM sodium pyruvate, 1X non essential amino acids, 5% 
penicillin/streptomycin solution (Gibco), and 10% FBS.  For oligonucleotide 
transfections, 48 hours pre-transfection, cells were plated to approximately 50% 
confluence in an appropriate dish size for the assay (approximately 2.5X106 cells 
per 10 cm dish,  5x105 cells/ well - 6 well dish, 2x105 cells/well - 24 well dish, and 
5x104 cells/well - 96 well dish).  Snap frozen human prostate cancer tissue 
samples were obtained from UNC’s Tissue Procurement Facility (Chapel Hill, 
NC).  Samples were thawed and small sections homogenized in TRI-Reagent 
(Sigma) for RNA isolation. 
 
SSO Treatment 
18-mer 2’-O-methyl-oligoribonucleoside-phosphorothioates (OMe SSOs; 
TriLink BioTechnologies) and 18-mer 2’-O-methoxyethoxy- oligoribonucleotide- 
phosphorothioates (MOE SSOs; ISIS Pharmaceuticals/IDTDNA) were targeted to 
the 5’ splice sites of exon 1 (SSO1OMe & SSO1MOE: 
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UACCGAAGAGGAAGCCGA), exon 6 (SSO6OMe & SSO6MOE: 
UAACCUGGUGUGAGAGGG), or exon 18 (SSO18OMe & SSO18MOE: 
AGGCCUGUCUGGUAACCC). 18-mer SSOs targeted to β-globin (705OMe & 
705MOE: CCACUUACCUCAGUUACA), a randomized sequence (RANDOM-
OMe: N18), and a 4 nucleotide mismatch to SSO1 (SSOMM-OMe & SSOMM-
MOE: UAACGAACAGGCAGGCGA) were used as negative controls. SSOs were 
delivered to cells (see figures for dosage and length of treatment) with 
Lipofectamine 2000 (Invitrogen) in the presence of 5% FBS according to 
manufacturer directions; SSO/Lipofectamine complex was not removed from 
cells throughout the duration of the transfection procedure.  
 
RNA Isolation 
Total RNA from treated and untreated cells was isolated with TRI-reagent 
(Molecular Research Center, Inc.) or the Gentra Systems Versagene™ RNA cell 
kit following the supplier protocols.  Briefly, for the TRI-reagent protocol, media 
was removed from cells.  Depending on well size, 250-500 µL TRI-reagent was 
added to cells and incubated at room temperature for 5-10 minutes.  1/10th 
volume 1-Bromo-3-chloropropane (BCP) was added to each volume of TRI-
reagent, vortexed for 30 seconds, incubated on ice for 2 minutes, and centrifuged 
at 14000 RPM for 15 minutes at 4° Celsius.  The top aqueous phase was 
transferred into 125-250 µL isopropanol with 1-2 µL Glycoblue (Invitrogen), 
inverted to mix and centrifuged at 14000 RPM for 10 minutes at 4° Celsius.  
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Supernate was removed and pellets washed with 125-250 µL ethanol.  RNA 
pellets were air dried and resuspended in 25-50 µL autoclaved distilled water. 
 
Reverse Transcription PCR (RT-PCR) 
500ng total RNA was used in the RT reaction with MuLV reverse 
transcriptase (Applied Biosystems) at 42°C for 15 minutes and 95°C for 5 
minutes to inactivate MuLV.  PCR, in the presence of approximately 0.2 µCi [α-
32P] dATP, or 1-2 pM Cy5-dCTP (Amersham Biosciences) and Platinum Taq 
polymerase (Invitrogen), was: 95°C, 2 minutes followed by 21 cycles of 95°C for 
30 seconds, 54°C for 30 seconds, 72°C for 1 minute.  The final PCR step was 
72°C, 7 minutes.  For detection of PSMA/PSM’ RT-PCR products, the forward 
and reverse primers were:  AAACACTGCTGTGGTGG, and 
TAGCTCAACAGAATCCAGGC, respectively, yielding 511 bp PSMA and 245 bp 
PSM’ products. These PCR reactions contained 6X PCR Enhancer with betaine 
(Epicentre) (Henke, Herdel et al. 1997).  For the PSMA/PSMA∆6 RT-PCR the 
forward primer was CTATGCACGAACTGAAGA, reverse, 
GAGCTTCTGTGCATCATAG, yielding 383 bp PSMA and 201 bp PSMA∆6 
product.  For the PSMA/PSMA∆18, the forward 
(TTCAGTGAGAGACTCCAGGACTTTG) and reverse, 
(CATTACGATTCTTTCTGAGTGAC) primers produced 358 bp and 261 bp 
products, respectively.  Under the above conditions the change in product levels 
is linear in response to RNA input and extent of splicing. The PCR products were 
electrophoresed on a 10% TBE polyacrylamide precast gel in the Novex Mini-
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Cell apparatus (Invitrogen).  Dried gels were autoradiographed with Kodak 
BioMax film or scanned using Typhoon 9600 imager (GE Healthcare). 
 
Protein Isolation and Immunoblotting 
Treated and control cells were grown in 3 cm (6 well) or 10 cm plates.  
Media was removed and cells lysed on the plate with 0.5 and 1 ml water, 
respectively. The suspension was collected, sonicated for 10-30 sec using a 
Branson sonicator at power setting #2.  Volume was increased to 2 ml and 
protein separated into membrane and cytosolic cell fractions by 
ultracentrifugation at 100,000g for 30 min using a Beckman Optima™ TL 
benchtop ultracentrifuge.  Pelleted membrane (F2) fraction was resuspended in 
250µL 1% SDS buffer.  Protein concentration in the fractions was determined 
using the Bicinchonic Acid Solution protein assay kit with Bovine Serum Albumin 
as standard (Sigma).  
For immunoblot analysis, 2-40µg protein was diluted to 40µl with 1X 
reducing reagent and 1X LDS sample buffer, incubated at 95°C for 5 min and 
electrophoresed on a 4-12% gradient NuPage Bis-Tris precast polyacrylamide 
gel.  The separated proteins were transferred onto Invitrolon PVDF membranes 
using the XCell II Blot Module. All reagents and instruments for immunoblot 
analysis were from Invitrogen (Carlsbad, CA).  
Proteins were detected with: YPSMA1 mAb, 1:1000 dilution (Yes 
Pharmaceuticals, Anogen); β-tubulin mAb, 1:3000 (Sigma); anti-P, E, N-Cadherin 
pAb, 1:1000 (Calbiochem).  Horseradish peroxidase conjugated anti-mouse 
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(Sigma) and anti-rabbit (Calbiochem) secondary antibodies were used where 
appropriate.  The membranes were developed with the ECL Western Blotting 
Detection reagents (Amersham Biosciences) and exposed to Kodak BioMax film. 
Immunoblot and RT-PCR images were processed and quantified with the NIH 
Image J software.     
 
PSMA NAALADase Activity Assay 
Membrane and cytoplasmic fractions were obtained as described above 
except that all procedures were carried out in 1X NAALADase reaction buffer: 
50mM Tris pH 7.4, 1mM CoCl2.   25µg protein was incubated with 2 mM NAAG 
in a volume of 100 µl for 24 h.  The enzymatic reaction was stopped with 250 mM 
sodium phosphate and samples frozen until assayed (Slusher, Robinson et al. 
1990; Schulke, Varlamova et al. 2003).  Free glutamate was assayed as 
described using a commercial L-glutamic acid quantitation kit (r-Biopharm, 
Darmstadt, Germany) according to the manufacturer’s instructions.   
 
Cellular Malignancy Assays (MTS, ATP, Caspase 3/7) 
 The CellTiter 96® AQueous One Solution Cell Proliferation assay (MTS), 
CellTiter-Glo® Luminescent Cell Viability assay (ATP), and Apo-ONE® 
Homogeneous Caspase-3/7 assay (Caspase 3/7) (all Promega) were performed 
in 96 well dishes according to manufacturer’s directions.  Black-well dishes were 
used for the luminescent and fluorescent assays.  Cells were plated 48 hours pre 
transfection and assayed 48 hours post transfection.  Percent readings were 
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based on the equation [(sample reading – blank reading)/(mock transcription 
reading – blank reading)] X 100%. 
 
Statistical Analysis 
 For analysis of splice switching oligonucleotide dose curves, EC50 values 
were calculated using non-linear regression analysis by the GraphPad Prism 
version 4 software.  All error bars indicate standard error of the mean (SEM). 
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CHAPTER 3 
Successful Modification of PSMA Splice Variants Using Splice Switching 
Oligonucleotides 
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I. Introduction 
Antisense oligonucleotides are now well established tools for gene 
regulation at the mRNA level.  Their sequence specificity, size, and chemical 
properties allow for efficient targeting of individual gene transcripts.  Antisense 
technology has mostly been used for downregulation of mRNA by recruiting 
RNase H.  When bound to target RNA, antisense oligonucleotides and RNA 
create an RNA/DNA duplex; RNase H recognizes this duplex as a potential 
cellular hazard and degrades the duplexed RNA.  mRNA transcripts targeted by 
antisense oligonucleotides are rendered useless since they are cleaved and 
truncated prior to the translation process.  Lesser utilized antisense 
oligonucleotide applications include blocking the maturation and transport of 
RNAs from the nucleus to the cytoplasm by targeting 5’ cap and 3’ 
polyadenylation sites and inhibiting translation by targeting the mRNA start codon 
(Crooke 2001). 
The primary research in this laboratory and a few others focuses on a 
novel and potentially therapeutic application of antisense oligonucleotide 
technology.  By targeting specific pre-mRNA splicing elements in the nucleus, 
antisense oligonucleotides are able to alter splicing patterns.  Use of this process 
promotes desired alternative splicing patterns and can not only downregulate 
specific targets, but can simultaneously increase levels of desired transcripts.  
This specific application of antisense oligonucleotides was first applied to the β-
globin gene by Dominski and Kole in 1993 (Dominski and Kole 1993).  Since 
then, the splice altering capacity of antisense oligonucleotides has been tested 
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and confirmed for several targets including bcl-x, CFTR, tau, β-globin, and others 
(Sierakowska, Sambade et al. 1996; Friedman, Kole et al. 1999; Kalbfuss, 
Mabon et al. 2001; Mercatante, Sazani et al. 2001).  Studies have shown the 
efficacy of splice-switching oligonucleotides not only in cultured cells, but also in 
vivo (Sazani, Gemignani et al. 2002; McClorey, Fletcher et al. 2005). 
The properties of Prostate Specific Membrane Antigen splice variants and 
its alternative splicing patterns make PSMA an intriguing target for splicing 
modulation by SSOs.  Even though PSMA is a relatively newly characterized 
gene and protein, several of its spliced products have been identified.  Most 
studies involving PSMA address the full length membrane bound transcript 
where all ‘normal’ exons are included and introns excluded.  This is the case 
even though one report maintains that this variant is not the primary transcript of 
the PSMA gene in some prostate tissues (Su, Huang et al. 1995). 
Figure 1.6 illustrates all of the identified alternative splice variants of 
PSMA.  Of these, PSMA is the best understood.  PSM’ has been at least partially 
characterized, while the properties of the other alternative splice products at the 
protein level have not been determined. 
In this study, the PSMA, PSM’, PSM∆6, and PSM∆18 variants are 
analyzed.  PSM’ is derived from a splicing pattern that utilizes the 3’ splice site of 
PSMA’s exon 2 and an alternate 5’ splice site in exon 1.  The start codon 
normally used for PSMA translation is ‘spliced out’ of PSM’ as part of the first 
intron; an alternate start codon located in exon 2 encodes the initial amino acid 
for the PSM’ protein.  PSM’ is missing the first 60
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Consequently, PSM’ does not have a transmembrane sequence and is localized 
to the cytoplasm instead of the plasma membrane.  Su et al. first demonstrated 
that PSM’ splicing predominates over PSMA in normal and benign prostate 
tissues tested.  However, the ratio of PSM’/PSMA splicing reverses in prostate 
cancer (Su, Huang et al. 1995).  A correlation also was drawn between a 
decrease in PSM’/PSMA ratio and increasing Gleason score and cancer 
metastasis (Schmittgen, Teske et al. 2003).  From these observations, it is clear 
that upregulation of PSMA and/or downregulation of PSM’ is related to 
malignancy of prostate tissues, but whether it is a causative factor or a 
consequence of malignancy remains to be determined.  Applying splice switching 
technology to alter the PSM’/PSMA splicing pattern will help to characterize this 
relationship.  
From PSMA sequence data we determined that removal of the sixth or 
eighteenth exons from the PSMA transcript causes a change in reading frame for 
the PSMA∆6 and PSMA∆18 splice variants compared to PSMA.  With PSMA∆6, 
the mRNA transcript encodes an early stop codon located upstream of the 
enzymatic and dimerization domains, while the usage of a novel stop codon in 
PSMA∆18 leaves the enzymatic domain intact while eliminating the dimerization 
domain.  Since it has been demonstrated that PSMA protein dimerization is 
required for its hydrolase and dipeptidase function (Schulke, Varlamova et al. 
2003), we hypothesize that splice switching from PSMA to either PSMA∆6 or 
PSMA∆18 will disrupt PSMA function.  However, both splice variants should 
maintain their membrane targeting potential if properly translated.   
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To induce splice switching from PSMA to the other three variants we 
utilize oligonucleotides with 2’-O-methyl (OMe) or 2’-O-methoxyethoxy (MOE) 
ribose conformations with phosphorothioate linkages (Figure 3.1 illustrates 
oligonucleotide chemistries).  These SSOs were targeted to the 5’ splice site of 
PSMA exons 1, 6, and 18.   
Initially, three different OMe oligonucleotide sequences per target were 
tested in order to increase the chances of finding efficient, effective sequences.  
For the PSMA to PSM’ shift, SSOs were targeted directly to the 5’ splice junction 
of exon 1; the three tested SSOs each included the splice junction with intron and 
exon sequence, but differed in exact position at the splice junction (Fig 3.2).   A 
more involved approach was taken to find SSO sequences for the PSMA to 
PSMA∆6 and PSMA∆18 shifts.  Here, SSOs were targeted to exon splicing 
enhancer (ESE) sequences at or adjacent to the 5’ splice sites.  Previous reports 
had demonstrated that the blocking of ESE sequences with oligonucleotides was 
capable of inducing splice switching (Errington, Mann et al. 2003; Takeshima, 
Yagi et al. 2005).  ESEfinder, a useful internet-based software, is able to analyze 
nucleic acid sequences to not only find ESEs, but quantify the strength of ESE 
sequences based on the recognition sequences of the SF2/ASF, SC35, SRp40, 
and SRp55 ESEs (Cartegni, Wang et al. 2003).  Approximately 500 nucleotide 
sequences surrounding the 5’ splice sites of PSMA’s exons 6 and 18 were 
analyzed by ESEfinder.  The graphic output of these analyses is shown in 
Figures 3.3 and 3.4.  Also detailed in the figures are the locations and sequences 
of SSOs selected for testing.  Of the nine original SSO sequences, the three that  
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Figure 3.1. Chemical structures of 2’-O-methyl and 2’-O-methoxyethoxy 
phosphorothioate oligonucleotides. 
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1 2TMD
5’5’
1 22TMD1
DNA Sequence
GCCGAGATGTGGAATCTCCTTCACGAAACCGACTCGGCTGT
GGCCACCGCGCGCCGCCCGCGCTGGCTGTGCGCTGGGGCGC
TGGTGCTGGCGGGTGGCTTCTTTCTCCTCGGCTTCCTCTTC
G / GTAGGGGGGCGCCTCGCGGAGCAAACCTCGGAGTCTT
CCCCGTGGTGCCGCGGTGCTGGGACTCGCGGGTCAGCTGCC
GAGTGGGATCCTGTTGCTGGTCTTCCCCAGGGGCGGCGATT
1A:   UAC  / CGA AGA GGA AGC CGA 
1B:   CCC UAC  / CGA AGA GGA AGC 
1C:   CCC CCC UAC  / CGA AGA GGA
Figure 3.2. SSO1 candidate sequence selection.   
 
18-mer oligonucleotide sequences were selected by their position at the 5’ 
splice junction of PSMA’s exon 1.   Candidate SSO1 sequences (1A, !B, 
and 1C) included the 5’ splice site junction with intronic and exonic 
sequence. 
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6A: UAA CCU GGU GUG AGA GGG
6B: CAU UCA C/CA UUU GCU GGG
6C: CAA GGA UUG AUC AUU CAC
SF2/ASF
SC35
SRp40
SRp55
Figure 3.3. SSO6 candidate sequence selection.   
 
Graphic ouput of ESEfinder software analysis of PSMA pre-mRNA sequence 
from exon 6 and intron 6.  Three 18-mer oligonucleotide sequences were 
selected for their localization near the 5’ splice junction and ESE recognition 
sequences.   The X-axis shows the pre-mRNA nucleotide sequence.  Colored 
bars indicate areas similar to the SF2/ASF, SC35, SRp40, and SRp55 ESE 
consensus sequences; height of bars is directly proportional to sequence 
similarity of ESE recognition sequences. The 6A oligonucleotide is positioned 
in the 6th exon at an ESE hotspot, 6B is positioned at the 5’ splice junction, 
and 6C is positioned in the 6th intron. 
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SF2/ASF
SC35
SRp40
SRp55
18A: ACU AUU GGG CUG AGA AAG
18B: AGG CCU GUC UGG UAA CCC
18C: CUU ACC UAU AAA AAG GCC
Figure 3.4. SSO18 candidate sequence selection.   
 
Graphic ouput of ESEfinder software analysis of PSMA pre-mRNA sequence 
from exon 18 and introns 17 and 18.  Three 18-mer oligonucleotide sequences 
were selected for their localization near exon 18’s 3’ and 5’ splice junction and 
ESE recognition sequences.  The X-axis shows the pre-mRNA nucleotide 
sequence.  Colored bars indicate areas similar to the SF2/ASF, SC35, SRp40, 
and SRp55 ESE consensus sequences; height of bars is directly proportional 
to sequence similarity of ESE recognition sequences. The 18A oligonucleotide 
is positioned at exon 18’s 3’ splice site, 18B is positioned in the 18 exon at an 
ESE hotspot, and 1C is positioned at exon 18’s 5’ splice site. 
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induced the best splice switching (one per target) were selected for use in this 
study (Fig. 3.5).   
II. Results 
A. PSMA to PSM’, PSMA∆6, and PSMA∆18 splice switching 
Levels of PSMA splice variants were determined by RT-PCR amplification 
using target specific primers that flank alternatively spliced regions.  Prostate 
tissue samples obtained from the University of North Carolina’s Tissue 
Procurement Facility were tested to determine in vivo levels of the PSMA, PSM’, 
PSMA∆6, and PSMA∆18 splice variants prior to SSO analysis (Fig. 3.6).  This 
step was important since the PSMA∆6 and PSMA∆18 mRNA levels had not been 
previously established.  Native levels of the PSMA and PSM’ splice variants in 
cell lines including prostate cancer PC3, CWR-R1, LNCaP and cervical cancer 
HeLa were also analyzed (Fig. 3.7).  Consistent with prior reports, LNCaP cells 
expressed a large amount of PSMA and PSM’ mRNA and the PSMA/PSM’ ratio 
was similar to that obtained from an RNase protection assay performed by Su et 
al. (Su, Huang et al. 1995).  Antisense 2’-O-methyl-phosphorothioate (OMe) and 
2’-O-methoxyethoxy-phosphorothioate (MOE) modified 18-mer SSOs were 
targeted to specific PSMA pre-mRNA sequences.  These SSO chemistries are 
able to hybridize strongly to target RNA, are resistant to cellular nucleases and 
do not induce RNase H degradation of SSO-bound RNA (Manoharan 1999).  To 
induce splice switching from the full length PSMA transcript to PSM’, 
PSMA∆6and PSMA∆18 splice variants, LNCaP cells were treated with SSO1, 
SSO6, or SSO18, respectively.    
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Figure 3.5. PSMA SSO 1, 6, and 18 selection.  
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Figure 3.5. PSMA SSO 1, 6, and 18 selection.   
 
Candidate OMe SSOs were tested in LNCaP cells for their ability to switch PSMA 
splicing patterns after 48 hour transfections.  RT-PCR analysis was of total 
cellular RNA using target specific primers.  A) SSOs 1A, 1B, and 1C were tested 
at 1µM, 0.5 µM, and 0.1 µM concentrations.  B) SSOs 6A, 6B, and 6C were 
tested using a 1:3 dose curve from 1 µM to 0.0041 µM concentrations.  C) SSOs 
18A, 18B, and 18C were tested using a 1:3 dose curve from 1 mM to 0.0041 mM 
concentrations.  SSOs 1A, 6A, and 18B were determined to be the most efficient 
at splice switching and were chosen to be SSOs 1, 6, and 18. 
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Figure 3.6. PSMA splice variant levels in prostate tumor samples.   
 
RT-PCR analysis using target specific primers for PSMA splice variants. A) 
Splice variants produced from alternative splicing involving PSMA’s intron 1 
detected using an exon1 forward primer and exon 2 reverse primer: PSMA, 
PSM’, PSMA-C, and PSMA-D.  B) PSMA and PSMA∆6 variants detected 
using primers in exons 5 and 7.  C) PSMA and PSMA∆18 variants detected 
using primers in exons 17 and 19.  Two prostate tumor samples were 
obtained from the Tissue Procurement Facility of the University of North 
Carolina. 
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Figure 3.7. PSMA and PSM’ splice variant levels in the PC3, 
CWR-R1, LNCaP, and HeLa cell lines.   
 
RT-PCR analysis using target specific primers for PSMA and PSM’.  
PSMA is not detected in the PC3 prostate cancer cell line or the HeLa 
cervical cancer cell line.  LNCaP cells express high levels of the two 
PSMA splice variants.  
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           Without SSO treatment, the endogenous PSM’ mRNA amount was 
approximately 22% to 28% of total, similar to a previous report (Su, Huang et al. 
1995).  The initial PSMA∆6 percentage was 4% to 6%, indicating that in LNCaP 
cells PSMA∆6 is a very minor PSMA splice variant.  The PSMA∆18 splice 
percentage of total was between 20% and 23%, i.e. at levels similar to the PSM’.  
RT-PCR analysis 48 hours post SSO transfection showed the desired, dose 
dependent decrease in PSMA mRNA and increase in PSM’, PSMA∆6, and 
PSMA∆18 splice variants (Figs. 3.8, 3.9, 3.10, 3.12, 3.13, 3.14).  The effects 
were sequence specific since there was no change in the levels of the splice 
variants in mock treated samples or in 1 µM 705 and negative control 
oligonucleotide (random/mismatch) treated samples. With SSO1, both the OMe 
and MOE chemistries induced similar amounts of splice switching in the dose 
curve analysis with the 0.3 µM dose being the only exception (Figs. 3.8 and 
3.12).  SSO1 was able to increase PSM’ transcript levels to 80% and 73% of total 
at the best dose for OMe and MOE chemistries, respectively.  The MOE SSOs 6 
and 18 were not as efficient as their equivalent OMe chemistry; they were able to 
increase PSMA∆6 and PSMA∆18 transcript levels to only about 75% and 85% of 
that accomplished by OMe SSOs 6 and 18.  However they were effective enough 
to increase PSMA∆6 and PSMA∆18 levels to 60% and 62% of total, respectively 
(Figs 3.13, 3.14).  The fact that for SSOs 1 and 6 with OMe chemistry, the splice 
switching activity diminished between 0.3 and 1µM OMe SSO is most likely 
attributed to surpassing the optimum charge ratio between the negatively 
charged oligonucleotides and positively charged cationic lipid used for cellular  
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Figure 3.8.  Dose curve of splice switching by PSMA SSO1 OMe.   
 
Upper panel:  RT-PCR analysis of total cellular RNA using target specific 
primers after 48 hour SSO1 OMe transfection.  
Lower panel: Quantitated results from RT-PCR analysis: Percent PSM’ 
mRNA of total.  The results are from three independent SSO treatments, 
error bars indicate SEM.   
Lanes 1: Untreated control LNCaP mRNA, Lanes 2 & 3: Negative control 
SSO1 OMe at 1µM concentration, Lanes 4-10: LNCaP cells transfected 
with SSO1 OMe at 0µM (Mock), 0.004µM, 0.01µM, 0.04µM, 0.1µM, 
0.3µM and 1µM. 
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Figure 3.9.  Dose curve of splice switching by PSMA SSO6 OMe.   
 
Upper panel:  RT-PCR analysis of total cellular RNA using target specific 
primers after 48 hour SSO6 OMe transfection.  
Lower panel: Quantitated results from RT-PCR analysis: Percent 
PSMA∆6 mRNA of total.  The results are from three independent SSO 
treatments, error bars indicate SEM.   
Lanes 1: Untreated control LNCaP mRNA, Lanes 2 & 3: Negative control 
SSO6 OMe at 1µM concentration, Lanes 4-10: LNCaP cells transfected 
with SSO6 OMe at 0µM (Mock), 0.004µM, 0.01µM, 0.04µM, 0.1µM, 
0.3µM and 1µM. 
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Figure 3.10.  Dose curve of splice switching by PSMA SSO18 OMe.   
 
Upper panel:  RT-PCR analysis of total cellular RNA using target specific 
primers after 48 hour SSO18 OMe transfection.  
Lower panel: Quantitated results from RT-PCR analysis: Percent PSMA∆18 
mRNA of total.  The results are from three independent SSO treatments, 
error bars indicate SEM.   
Lanes 1: Untreated control LNCaP mRNA, Lanes 2 & 3: Negative control 
SSO18 OMe at 1µM concentration, Lanes 4-10: LNCaP cells transfected 
with SSO18 OMe at 0µM (Mock), 0.004µM, 0.01µM, 0.04µM, 0.1µM, 0.3µM 
and 1µM. 
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delivery; this decrease in SSO activity at high concentration was not detected for 
the MOE chemistry.  
The data from several independent RT-PCRs used to calculate the EC50 
values for each SSOs indicate that for the OMe chemistry, SSO18 was the most 
effective at splice shifting with an EC50 of 1.9 nM; SSOs 1 and 6 gave EC50 
values of 5.6 nM, and 3.5 nM, respectively.  Time course experiments using 0.3 
µM of each OMe SSO confirmed a persistent modulation of PSMA pre-mRNA 
splicing up to 96 hours (Fig. 3.11).   The effects increased until 48 hours, and 
then subsequently decreased, presumably due to SSO decay or its dilution in 
dividing LNCaP cells.  With the MOE chemistry, SSO1 had the lowest EC50 value 
of 2.1 nM while the EC50 for SSO6 was 18.8 and SSO18 was 6.25. 
B. PSMA and PSM’ protein expression in OMe SSO treated cells 
The consequences of PSMA pre-mRNA splicing modulation were 
analyzed at the protein level by immunoblot analysis of cytoplasmic and 
membrane fractions of OMe SSO treated LNCaP cells. The YPSMA1 mAb used 
in these experiments detects both PSMA and PSM’ because its epitope, near the 
C-terminus, at amino acids 716-723 of PSMA (Zhu et al. 1999), is retained in 
both proteins.  However, YPSMA1 cannot detect the PSMA∆6 or PSMA∆18 
proteins since both their mRNA transcripts contain stop codons upstream of the 
terminal amino acid sequence. 
  PSMA is a type II transmembrane protein and therefore the PSM’ splice 
variant, lacking a transmembrane domain, is expected to be retained in the 
cytoplasm. Indeed, a shift in PSMA pre-mRNA splicing induced by OMe SSO1  
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Figure 3.11.  Time course of splice switching by PSMA OMe SSOs.  
 
LNCaP cells were transfected with either SSO1, SSO6, or SSO18 at a 
concentration of 0.3µM.  RNA was harvested at 6, 12, 24, 48, 72 and 96 
hours post transfection. RT-PCR was performed using target specific 
primers and quantitated to determine splice variant percentage.  
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increased the level of PSM’ in the cytoplasmic fraction by 133% over mock (Fig. 
3.15, lane 3).  Although, at the mRNA level, there was a clear decrease of PSMA 
mRNA post SSO1 treatment, that effect was less evident with PSMA protein in 
the membrane fraction (Fig 3.15, lane 7), presumably reflecting the long half-life 
of membrane PSMA protein.   The effect of LNCaP cell treatment with OMe 
SSO6 as detected by immunoblot, was a 68% to 79% decrease of PSM’ and 
PSMA proteins in the cytoplasm and membrane fractions (Fig. 3.15, lanes 4, 8). 
The decrease of PSMA reflects, as noted above, a more effective shift in PSMA 
pre-mRNA splicing by OMe SSO6 than OMe SSO1.  The PSMA∆6 splice variant 
protein was not detected because the truncated PSMA∆6 protein lacks the 
YPSMA1 mAb epitope. Note that PSMA∆6 protein is not likely to be functional 
and therefore the effect of SSO6 is presumably limited to elimination of PSMA 
and PSM’ (see the discussion section of this chapter).  Similar results were seen 
after OMe SSO18 treatment though the decline in PSMA product in the 
membrane fraction was less pronounced compared to OMe SSO6 (Fig 3.15, 
lanes 5, 9).  Again, the YPSMA1 mAb did not detect the generated PSMA∆18 
variant due to alteration of the C-terminal amino acid sequence.  Nevertheless, 
the downregulation of PSM’ and PSMA after OMe SSO6 and SSO18 treatment 
verify splice switching activity of both oligonucleotides at the protein level. 
C. Function of PSMA and PSM’ in OMe SSO treated cells 
Cytoplasmic and membrane fractions of LNCaP cells, treated with OMe 
SSO1, SSO6 or SSO18 at a concentration of 0.3 µM for 48 hours, were assayed 
for PSMA protein dipeptidase activity. N-acetyl-aspartyl-glutamate (NAAG) was  
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Figure 3.12.  Dose curve of splice switching by PSMA SSO1 MOE.   
 
Upper panel:  RT-PCR analysis of total cellular RNA using target specific 
primers after 48 hour SSO1 MOE transfection.  
Lower panel: Quantitated results from RT-PCR analysis: Percent PSM’ 
mRNA of total.  The results are from three independent SSO treatments, 
error bars indicate SEM.   
Lanes 1: Untreated control LNCaP mRNA, Lanes 2 & 3: Negative control 
SSO1 MOE at 1µM concentration, Lanes 4-10: LNCaP cells transfected 
with SSO1 MOE at 0µM (Mock), 0.004µM, 0.01µM, 0.04µM, 0.1µM, 
0.3µM and 1µM. 
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Figure 3.13.  Dose curve of splice switching by PSMA SSO6 MOE.   
 
Upper panel:  RT-PCR analysis of total cellular RNA using target specific 
primers after 48 hour SSO6 MOE transfection.  
Lower panel: Quantitated results from RT-PCR analysis: Percent 
PSMA∆6 mRNA of total.  The results are from three independent SSO 
treatments, error bars indicate SEM.   
Lanes 1: Untreated control LNCaP mRNA, Lanes 2 & 3: Negative control 
SSO6 MOE at 1µM concentration, Lanes 4-10: LNCaP cells transfected 
with SSO6 MOE at 0µM (Mock), 0.004µM, 0.01µM, 0.04µM, 0.1µM, 
0.3µM and 1µM. 
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Figure 3.14.  Dose curve of splice switching by PSMA SSO18 MOE.   
 
Upper panel:  RT-PCR analysis of total cellular RNA using target specific 
primers after 48 hour SSO18 MOE transfection.  
Lower panel: Quantitated results from RT-PCR analysis: Percent 
PSMA∆18 mRNA of total.  The results are from three independent SSO 
treatments, error bars indicate SEM.   
Lanes 1: Untreated control LNCaP mRNA, Lanes 2 & 3: Negative control 
SSO18 MOE at 1µM concentration, Lanes 4-10: LNCaP cells transfected 
with SSO18 MOE at 0µM (Mock), 0.004µM, 0.01µM, 0.04µM, 0.1µM, 
0.3µM and 1µM. 
 86 
used as a substrate and the released free glutamate was measured 
colorimetrically as described in the Materials and Methods chapter. OMe SSO1 
treatment, consistent with the generation of functional PSM’ splice variant, 
resulted in a 30% increase of cytoplasmic activity and a 10% decrease in 
membrane PSMA activity (the latter result is within statistical error, Fig. 3.16). 
After OMe SSO6 and OMe SSO18 treatment, both cytoplasmic and membrane 
fractions showed significantly decreased levels of PSMA function (Fig. 3.16).  
Also in line with the results seen at the protein level, the decline in PSMA activity 
after OMe SSO18 treatment was not as pronounced as that seen with OMe 
SSO6.  
III. Discussion 
We have found that in LNCaP cells, SSO-induced shifts in splicing drove 
expression of PSMA mRNA and protein from the malignancy-associated 
membrane bound variant to other lesser expressed variants, including 
cytoplasmic PSM’ and truncated, presumably non-functional PSMA∆6 and 
PSMA∆18. This change was also reflected in the shift in NAALADase activity of 
PSMA. The EC50 of SSOs 1, 6 and 18 are listed in table 3.1; the splice switching 
efficiency of SSOs may be improved if oligonucleotides with higher Tm values, 
for example, with PNA and LNA backbones (Sazani, Gemignani et al. 2002; 
Sazani, Dillman and Kole, unpublished) are used.  
The increase in PSM’ NAALADase activity in the cytoplasmic fraction of 
OMe SSO1 treated cells indicates that SSO induced PSM’ retained its enzymatic 
function. In view of the recent reports that dimerization of PSMA or of its  
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Table 3.1  Properties of PSMA SSOs 
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Figure 3.15.  Western blot analysis of PSMA protein from OMe SSO 
transfected cells.  
 
Total cellular protein was isolated from LNCaP cells 48 hours post 
transfection with 0.3 µM OMe SSOs 1, 6, or 18. Cytoplasmic and 
membrane fractions were separated by ultracentrifugation (see Materials 
and Methods).   
Upper panel: PSMA protein (40 µg for cytoplasmic fraction, 2 µg for 
membrane fraction and total protein),  
Middle panel: 10 µg Cadherin protein for membrane fraction identification,  
Lower panel: 2 µg β-tubulin protein for cytoplasmic fraction identification.   
Lane 1, total untreated PSMA protein, Lanes 2 & 6: mock treated cells, 
Lanes 3 & 7 SSO1, Lanes 4 & 8 SSO6, Lanes 5 & 9, SSO18 treatment.  
Lanes 2-5 cytoplasmic section, Lanes 6-9 membrane section. 
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Figure. 3.16. L-glutamate cleavage in cytoplasmic and membrane 
fractions after OMe SSO treatment.   
 
LNCaP cells were transfected with 0.3 µM of either SSO1, SSO6, SSO18, 
negative control 705 SSO, or mock treated for 48 hours.  Protein was 
separated into cytoplasmic and membrane fractions.  Fractions were 
assayed colorimetrically for NAALADase activity as measured by the 
amount of l-glutamate cleaved from the NAAG molecule after a 24 hour 
incubation. 
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extracellular domain is essential for activity (Schulke, Varlamova et al. 2003; 
Davis, Bennett et al. 2005) it follows that PSM’ forms a homodimer in the 
cytoplasm.  Enzymatic activity of PSM’ was recently questioned because of its 
incompatible glycosylation pattern (Ghosh, Wang et al. 2005). The reason for this 
discrepancy with our results is not clear.  
Since cytoplasmic PSM’ retains activity in OMe SSO1 treated LNCaP 
cells, it is conceivable that PSM’ may have a suppressor-like role in normal 
prostate cells. Its expression should lead to hydrolysis of cytoplasmic 
polyglutamed folate stores, freeing cellular folates for efficient export (Osborne, 
Lowe et al. 1993).  This would affect cellular one carbon metabolism including 
DNA and RNA synthesis (Wagner 1995) possibly altering the cell cycle and 
apoptosis. The possible pro-apoptotic effects of expression of folate metabolism 
enzymes are not limited to PSM’. 10-formyltetrahydro-folate dehydrogenase 
(FDH) is highly expressed in a number of tissues, including prostate, and virtually 
eliminated in most tumor tissues and cell lines.  Transient transfection of FDH 
inhibited growth of cancer cells (Krupenko and Oleinik 2002).  
In LNCaP cells, the level of PSMA expression is very high as transcription 
of the gene is enhanced 140 fold in cancer versus normal prostate cells (Ghosh 
and Heston 2004). In consequence, SSO1-induced PSM’ levels and its potential 
effect on folate metabolism will be much higher than in non-malignant prostate 
tissue.  This observation points out the potential strength of the SSO approach in 
this system.  If PSMA plays a role in the malignancy of prostate cells, they should 
be more sensitive to the SSO1 treatment; the cells that do not express PSMA will 
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be resistant. Thus, if SSO1 were to be used clinically, the side effects should be 
low and the therapeutic index high.  
This report is the first to examine the PSMA∆6 and PSMA∆18 splice 
variants.   Both variants are produced in LNCaP cells and are readily detectable 
by RT-PCR. Since the initial level PSMA∆6 is very low, its role in LNCaP cells is 
not clear.  However, PSMA∆18 and PSM’ transcripts are expressed natively at 
about 33% of PSMA, suggesting a function in relation to PSMA.  RT-PCR 
analysis of the RNA from cells treated with SSO6 shows that PSMA mRNA was 
strongly decreased and PSMA∆6 mRNA strongly increased.  There was a 
concomitant, and expected, decrease of PSMA protein but we were unable to 
detect the PSMA∆6 protein splice variant using a different polyclonal PSMA 
antibody (Williams and Kole, unpublished), suggesting that that protein was not 
properly translated or was unstable.  Even if expressed, the truncated PSMA∆6 
would lack the catalytic site while both PSMA∆6 and PSMA∆18 lack the 
dimerization domain.  Therefore, neither variant should have enzymatic activity.  
PSMA is potentially a membrane signaling or a transport protein because 
of its cytoplasmic MXXXL internalization motif and its ability to internalize in 
response to ligand binding (Rajasekaran, Anilkumar et al. 2003).  This is 
supported by the observation that aptamers bound to PSMA’s extracellular 
region are transported internally and dispersed in the cytoplasm of LNCaP cells 
(Lupold, Hicke et al. 2002).  Both the PSMA∆6 and PSMA∆18 splice variants 
would retain this MXXXL motif and could interfere with normal membrane PSMA 
signaling, giving a dominant negative effect.  Until this hypothesis is further 
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examined, one concludes that any effects of SSO6 and SSO18 treatment on 
LNCaP cells are due to a decrease in PSMA alone. 
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CHAPTER 4 
PSMA Splice Switching Effects on Malignancy of LNCaP Cells 
 94 
I. Introduction 
Cancer originates and progresses in response to a series of genetic 
alterations that are responsible for oncogene activation and/or inactivation of 
tumor suppressors and DNA repair regulators.  This process though does not 
account for several other factors including epigenetic changes, post-
transcriptional and post-translational regulation of protein expression, and the 
influence of tissue microenvironment (Clemens 2004; Feinberg, Ohlsson et al. 
2006).  Cellular proteins that influence or are influenced by these types of 
changes are not as readily or directly associated with malignancy since a 
cause/effect relationship is not always well established.  Cancer biomarkers, or 
proteins whose expression levels are linked to an increased risk of cancer or 
progression of disease, may be useful for more than cancer diagnosis, 
screening, and staging; with increased investigation into their biological function 
and the basis of their modulation of expression with cancer, biomarkers may be 
implicated as oncogenes, tumor suppressors, or as accessory elements capable 
of influencing other aforementioned factors related to the initiation and/or 
advancement of malignancy.  For example, expression levels of human chorionic 
gonadotrophin-β (hCG-β) are used to diagnose and monitor testicular and other 
types of cancer.  hCG-β is considered a very sensitive cancer marker and 
specific assays that monitor hCG-β in serum, urine, and tumor tissue are 
currently in use (reviewed in Stenman, Alfthan et al. 2004).  While most studies 
into its expression focus only on its use as a biomarker, hCG-β has been shown 
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to increase tumor cell proliferation by preventing apoptosis in tissue culture cells 
(Butler, Ikram et al. 2000).  hCG-β’s role may surpass biomarker to oncogene 
status and it could eventually be targeted for molecular therapy instead of simply 
being used for cancer diagnosis and staging.  
PSMA is considered a biomarker of prostate cancer because its increased 
expression is correlated to prostate cancer grade, stage, and hormone 
insensitivity (Wright, Grob et al. 1996; Kawakami and Nakayama 1997; Bostwick, 
Pacelli et al. 1998; Schmittgen, Teske et al. 2003).  Also, its presence in tumor 
neovasculature and absence in normal vasculature point to a potential link 
between PSMA and tumor maintenance (Liu, Moy et al. 1997; Silver, Pellicer et 
al. 1997; Chang, Reuter et al. 1999).  Prostate malignancy may be directly 
influenced by PSMA expression; regulation of PSMA expression, particularly by 
alternative splicing, could be a key determinant of cancer initiation and/or 
progression.   
Malignancy can be described as the sum of the acquired molecular and 
cellular changes that cancer cells gain to overcome regulation in growth, 
differentiation, and cell death.  Although malignancy is relatively simple to define, 
the specific processes involved in malignant transformation and perpetuation are 
still being discovered and described.  Hanahan and Weinberg suggested six 
categories of cellular changes that must be realized to achieve malignancy: “self-
sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) 
signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis” (Hanahan 
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and Weinberg 2000).  Clinically, malignancy is correlated to tumor size, lymph 
node involvement, and presence of metastases in the TNM staging system 
(Sobin 2003; Gospodarowicz, Miller et al. 2004).   In this study LNCaP cells are 
used for their high expression of PSMA and fortunately, they readily exhibit the 
major hallmarks of malignancy.  LNCaP cells are derived from a human lymph 
node metastasis of prostatic adenocarcenoma and can form tumors when 
injected into nude mice (Horoszewicz, Leong et al. 1983).   
We have successfully targeted PSMA pre-mRNA with three different SSO 
sequences of two different backbone chemistries to induce splice switching from 
the full length PSMA transcript to the PSM’, PSM∆6, and PSM∆18 variants in 
LNCaP cells.  Treatment with SSO1 was able to alter PSMA splicing and 
increase cytoplasmic PSM’ protein level while simultaneously decreasing 
membrane-associated PSMA expression.  Both SSOs 6 and 18 treatment 
increased PSMA∆6 and PSMA∆18 transcript levels, respectively, and induced 
downregulation of PSMA and PSM’ protein.  To determine if modulation of PSMA 
splicing by SSOs has an effect on LNCaP malignancy, cells were tested for 
alterations in proliferation and apoptosis post SSO transfection.  PC3 cells, which 
do not express PSMA, were used as a control to verify specificity of SSO effects. 
II. Results 
A. Cellular proliferation/viability after SSO Treatment 
 LNCaP and PC3 cells were transfected with 2’-O-methyl (OMe) and 2’-
O’methoxyethoxy (MOE) phosphorothioate SSOs at varying concentrations using 
the Lipofectamine 2000 (Invitrogen) cationic lipid delivery agent for 48 hours.  
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Splice switching of PSMA from the full length transcript to PSM’, PSMA∆6, and 
PSMA∆18 by SSO1, SSO6 and SSO18, respectively, were previously verified at 
the mRNA, protein, and PSMA functional level (see Chapter 3).  Post 
transfection, levels of cellular proliferation and viability were determined using a 
colorimetric metabolism assay and a luminescent ATP quantitation method.  The 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) directly 
measures cellular metabolism by utilizing a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] (MTS) and an electron coupling reagent phenazine ethosulfate 
(PES).  The MTS compound is reduced into a formazan molecule by NADPH or 
NADH in viable, active cells.  Formazan is a soluble and colored compound in 
tissue culture medium; levels of formazan produced after the addition and 
conversion of MTS are determined by measuring absorbance at wavelength 490 
nm.  Cell number/metabolism is directly proportional to absorbance readings.   
 Figures 4.1 and 4.2 show the results of the MTS proliferation assay after 
PSMA SSO treatment of LNCaP and PC3 cells.  Percent proliferation is based on 
readings at 490 nm compared to mock (Lipofectamine 2000 only) treatment.  In 
LNCaP cells, OMe SSOs 1, 6, and 18 all induced a decline in cellular 
proliferation at 48 hours (Fig. 4.1).  SSO1 gives the most prominent effect with a 
60% decrease in MTS metabolism at the highest concentration (1 µM); OMe 
SSOs 6 and 18 also had substantial effects on LNCaP proliferation.  The greatest 
effects observed were a 53% decline at 0.3 µM for SSO6 and a 50% decline at 1 
µM for SSO18.  However, the negative control OMe oligonucleotides, 705  
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Figure. 4.1.  MTS analysis after OME SSO treatment in LNCaP and PC3 
cells.   
 
LNCaP and PC3 cells were treated with OMe SSOs 1, 6, and 18, and 
control oligonucleotides using a 1:3 dose curve from 1 µM to 0.041 µM.  
Post transfection cells were assayed for proliferation/ total cellular 
metabolism using the colorimetric CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega).  Absorbance readings detected at 490 nm is 
directly proportional to total metabolism; percent metabolism is based on 
oligonucleotide treatment absorbance readings compared to mock treatment 
absorbance. 
 99 
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0 0.2 0.4 0.6 0.8 1 1.2
SSO1 
SSO6
SSO18
705o
NEG
LnCap
PC3
[2’MOE Oligo] µM
20%
30%
40%
50%
60%
70%
80%
90%
100%
110%
0 0.2 0.4 0.6 0.8 1 1.2
SSO1 
SSO6
SSO18
705o
NEG
Pe
rc
en
t M
TS
 
M
et
ab
ol
is
m
 
Pe
rc
en
t M
TS
 
M
et
ab
ol
ism
 
Figure. 4.2.  MTS analysis after MOE SSO treatment in LNCaP and PC3 
cells.   
 
LNCaP and PC3 cells were treated with MOE SSOs 1, 6, and 18, and 
control oligonucleotides using a 1:3 dose curve from 1 µM to 0.041 µM.  Post 
transfection cells were assayed for proliferation/ total cellular metabolism 
using the colorimetric CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (Promega).  Absorbance readings detected at 490 nm is directly 
proportional to total metabolism; percent metabolism is based on 
oligonucleotide treatment absorbance readings compared to mock treatment 
absorbance. 
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(targeted to the β-globin gene) and Random (N18) /MM (SSO1 four nucleotide 
mismatch) also caused a decrease in cellular MTS metabolism.  At most 
concentrations, negative control SSO effects were not as pronounced as 
targeted SSOs, but they were large enough to question the specificity of the 
relationship between PSMA splice switching and observed cellular effects.  To 
further examine the validity of this relationship, MOE SSOs of the same 
sequence were tested in LNCaP cells (the decision to use the MOE chemistry is 
outlined in this chapter’s discussion section); also both OMe and MOE SSOs 
were tested in PSMA negative PC3 cells (Figs. 4.1 and 4.2).  The results of these 
studies confirm effects not related to PSMA splice switching of OMe 
oligonucleotides on LNCaP cells.  First, OMe SSOs produced a similar decrease 
in MTS metabolism post transfection in PC3 cells, with SSO1 again giving the 
greatest effect.  Moreover, the MOE SSOs of the same sequence that induced 
similar levels of splice switching at the mRNA level as OMe SSOs had very little 
if any effect on cellular proliferation as measured by MTS metabolism in both 
LNCaP and PC3 cells (Fig. 4.2). 
 The level of ATP, the predominant energy storage molecule of the cell, is 
one of the most direct measures of cellular metabolism.  Here, ATP levels are 
correlated to cellular proliferation since abundance of ATP is directly related to 
the number of cells in culture (Crouch, Kozlowski et al. 1993).  The CellTiter-
Glo® Luminescent Cell Viability Assay (Promega) provides an accurate readout 
of ATP levels by taking advantage of the light-emitting potential of the luciferin 
molecule.  A recombinant firefly luciferase enzyme catalyzes the oxygenation of  
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Figure. 4.3.  ATP content analysis after OME SSO treatment in LNCaP 
and PC3 cells.   
 
LNCaP and PC3 cells were treated with OMe SSOs 1, 6, and 18, and 
control oligonucleotides using a 1:3 dose curve from 1 µM to 0.041 µM.  
Post transfection cells were assayed for cellular proliferation using the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega).  
Luminescence produced is directly proportional to cellular proliferation; 
percent proliferation is based on oligonucleotide treatment luminescence 
readings compared to mock treatment luminescence. 
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Figure. 4.4.  ATP content analysis after MOE SSO treatment in LNCaP 
and PC3 cells.   
 
LNCaP and PC3 cells were treated with MOE SSOs 1, 6, and 18, and 
control oligonucleotides using a 1:3 dose curve from 1 µM to 0.041 µM.  
Post transfection cells were assayed for cellular proliferation using the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega).  Luminescence 
produced is directly proportional to cellular proliferation; percent proliferation 
is based on oligonucleotide treatment luminescence readings compared to 
mock treatment luminescence. 
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beetle luciferin in the presence of ATP, magnesium, and molecular oxygen; 
oxyluciferin, AMP, diphosphate, carbon dioxide and light are the products of the 
reaction.  The luminescence or amount of light produced is directly related to 
ATP present when luciferin is in excess.  After oligonucleotide transfections, 
LNCaP and PC3 cells were lysed and total ATP levels were accessed.  The 
results of this luminescent ATP assay after OMe and MOE SSO1, 6, and 18 
treatments mostly echoed data from the MTS proliferation assay.  The total 
amount of ATP detected did decline significantly after 48 hour of transfection with 
all OMe SSOs and controls in both LNCaP and PC3 cells, although the effect 
was more prominent in LNCaP cells (Fig 4.3).  Using the same sequences with 
MOE chemistry, changes in ATP content were not impressive in both cell lines 
with none of the treatments giving more than a 15% decrease in LNCaP cells or 
an 8% decrease in PC3 cells (Fig. 4.4).  Again, these results indicate that the 
SSO oligonucleotide effects induced are not specific to the manipulation of 
PSMA splice variants. 
B. Apoptosis induction after SSO treatment 
 LNCaP and PC3 cells were treated with SSO and control oligonucleotides 
as previously described.  Levels of apoptosis, or programmed cell death, were 
measured 48 hours post treatment using a caspase 3/7 detection assay. 
 The ability of cancer cells to avoid apoptotic death by apoptosis is a key 
measure of malignancy that must be acquired in addition to proliferation to buffer 
against cellular attrition rates.  Apoptosis is marked by several biochemical and 
physical changes, including activation of cellular proteases called cysteine 
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aspartic acid-specific proteases (caspases), disruption of mitochondrial and 
plasma membranes, chromosome degradation, cell surface phosphatidylserine 
exposure, and cell shrinkage (recently reviewed in Gerl and Vaux 2005; 
Vermeulen, Van Bockstaele et al. 2005).  Accurate detection of apoptosis is best 
achieved by measuring several of these processes since not all are required 
and/or sufficient for apoptosis.  Here, we utilize the Apo-ONE® Homogeneous 
Caspase-3/7 assay (Promega) to determine levels of active caspases 3 and 7 as 
a measure of apoptosis.  Caspases are considered ‘active’ after they are cleaved 
from the inactive pro-caspase form and able to act on downstream effectors such 
as poly-(ADP ribose) polymerase (PARP), protein kinase C (PKC), 
topoisomerases, and other caspases (Vaux and Strasser 1996; Nicholson and 
Thornberry 1997).  Caspase 3 is able to cleave and activate downstream 
caspases 2, 6, 7, 8, 9, and 10 (Slee, Harte et al. 1999).  Janicke et al. 
demonstrated that caspase 3 activity are necessary for DNA fragmentation in the 
MCF-7 breast cancer cell line (Janicke, Sprengart et al. 1998) and detailed the 
many possible effects of caspase 3 in apoptosis signaling (Porter and Janicke 
1999).  Caspase 7 is considered a caspase 3-like protease with the same 
substrate recognition (Nicholson and Thornberry 1997; Talanian, Quinlan et al. 
1997).  In the caspase 3/7 assay, a pro-fluorescent substrate of caspase 3 and 7, 
Z-DEVD-R110 [rhodamine 110, bis-(N-CBZ-L- aspartyl-L- glutamyl- L- valyl-L- 
aspartic acid amide)], is cleaved after a cell lysis step.  The rhodamine 110 group 
is released and fluoresces with excitation at 499 nm.  Fluorescence emitted at 
521 nm is directly proportional to caspase 3/7 activity.  Interestingly, caspase 3/7 
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activity increased with all oligonucleotides tested in both LNCaP and PC3 cell 
lines.  With OMe SSOs and controls, large increases in caspase 3/7 activity were 
detected with a 14 fold upsurge over mock treatment in LNCaP and PC3 cells, 
respectively (Fig. 4.5).  Again, MOE oligonucleotides did not have an impact on 
cells to the extent of their OMe counterparts; they produced a more modest 3.25 
and 2.4 fold increase in LNCaP and PC3 cells, respectively (Fig. 4.6).  Also, as 
the graphs illustrate, there were no significant differences between the readings 
of SSOs and negative controls with both chemistries in both cell types.   
The evidence for non-specific effects of OMe oligonucleotides was 
overwhelming; no verifiable link between manipulation of PSMA splice ratio by 
SSOs and cellular proliferation/apoptosis level could be established. 
III. Discussion 
 Here, LNCaP cells were tested for changes in cellular proliferation and 
apoptosis rates post PSMA specific 2’-O-methyl and 2’-O-methoxyethoxy 
phosphorothioate SSO treatment using three different assays: 1) a MTS cell 
viability assay, 2) an ATP content assay, 3) and a caspase 3/7 assay.  The 
PSMA-less PC3 prostate tumor cell line, and negative control oligonucleotides, 
were used under the same conditions to subtract non-PSMA specific effects of 
SSO treatment.  We previously had demonstrated effective splice switching of 
PSMA at the mRNA level using SSOs 1, 6, and 18 over a range of 
oligonucleotide concentrations up to 1 µM after 48 hours.  Modest changes in 
PSMA and PSM’ protein level consistent with, but not as prominent as, the 
mRNA shift were observed using 0.3 µM of the 2’-O-methyl SSOs.  The three  
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Figure. 4.5.  Caspase 3/7 analysis after OME SSO treatment in LNCaP 
and PC3 cells.  
 
LNCaP and PC3 cells were treated with OMe SSOs 1, 6, and 18, and 
control oligonucleotides using a 1:3 dose curve from 1 µM to 0.041 µM.  
Post transfection cells were assayed for apoptosis by detecting active 
caspase 3/7 levels using the fluorescent Apo-ONE® Homogeneous 
Caspase-3/7 assay (Promega). Fluorescence produced is directly 
proportional to active caspase 3/7 levels; percent apoptosis is based on 
oligonucleotide treatment fluorescence readings compared to mock 
treatment fluorescence. 
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Figure. 4.6.  Caspase 3/7 analysis after MOE SSO treatment in LNCaP 
and PC3 cells.   
 
LNCaP and PC3 cells were treated with MOE SSOs 1, 6, and 18, and 
control oligonucleotides using a 1:3 dose curve from 1 µM to 0.041 µM.  
Post transfection cells were assayed for apoptosis by detecting active 
caspase 3/7 levels using the fluorescent Apo-ONE® Homogeneous 
Caspase-3/7 assay (Promega). Fluorescence produced is directly 
proportional to active caspase 3/7 levels; percent apoptosis is based on 
oligonucleotide treatment fluorescence readings compared to mock 
treatment fluorescence. 
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assays used to evaluate specific aspects of LNCaP malignancy were performed 
using the same dose range and 48 hour time point.  In LNCaP cells the 2’-O-
methyl SSOs induced a marked decline in cellular proliferation and increased in 
apoptosis, however these effects were not limited to PSMA specific 
oligonucleotides; both control 2’-O-methyl negative control oligonucleotides gave 
a similar effect.  Additionally, 2’-O-methoxyethoxy oligonucleotides of the same 
SSO1, 6, and 18 sequences failed to produce any significant changes in LNCaP 
proliferation and apoptosis compared to mock (no oligonucleotide) or negative 
control oligonucleotide treated cells.  One could argue that the effects of SSO1 
could be PSMA specific since they consistently produced a more pronounced 
effect on proliferation and apoptosis compared to the other SSOs and control 
oligonucleotides.  However, results of PC3 treated cells refute this conclusion 
and further detail the non-specific effects of PSMA targeted SSOs; 
measurements after PC3 transfections were similar to those from LNCaP 
treatment even exhibiting the enhanced effect of SSO1 even though PC3 cells 
lack PSMA. 
 Explanation of the dissimilarity in results from the two different SSO 
chemistries continues to be speculative.  The 18-mer sequences of SSOs 1, 6, 
and 18 were identical and their backbone chemistries contained all 
phosphorothioate linkages.  What remains is the difference in ribose modification, 
chemical synthesis, and possible presence of contaminants.  Current literature 
shows no evidence of any inherent toxicity with 2’-O-methyl oligonucleotides in 
cell culture at the concentrations used in this study.  TriLink BioTechnologies 
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(San Diego, CA), the manufacturer of the 2’-O-methyl oligonucleotides used 
here, confirmed their confidence in a lack of toxicity.  Note that while all 
oligonucleotides were purified by HPLC prior to our handling, two different 
companies were used to obtain the two sets of oligonucleotides.  The 2’-O-
methoxyethoxy oligonucleotides were obtained from Isis Pharmaceuticals 
(Carlsbad, CA), the sole provider of the chemistry, using IDTDNA (Coralville, IA) 
as their distributor.  We cannot discount or verify any differences in 
oligonucleotide quality based on synthesis that may have an effect on cells in 
culture.  An effort was made to identify contaminants in 2’-O-methyl 
oligonucleotide solutions using PAGE separation followed by visualization with a 
UV shadowing technique.  Single bands consistent with oligonucleotide size were 
detected with no visual contaminants, although this process cannot rule out the 
presence of small molecule contaminants.   
Initially, only 2’-O-methyl SSOs and controls were utilized in this study.  
The 705 negative control oligonucleotide consistently showed little effect on 
LNCaP cells after MTS analysis, a result not shared with other negative controls.  
After tracking the origin of the 705 sample, we determined that it was mislabeled 
as 2’-O-methyl, and was possibly of 2’-O-methoxyethoxy chemistry.  A chemical 
comparison was made using mass spectrometry of oligonucleotides with the 705 
sequence of both chemistries.  The spectrometry profile of the ‘unknown’ 705 
oligonucleotide was highly similar to that of the 705 2’-O-methoxyethoxy (Fig. 
4.7).  To increase the validity of our results, 2’-O-methoxyethoxy SSOs and 
controls were added to the study.  
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Figure. 4.7.  Mass spectrometry of 705 negative control 
oligonucleotide samples.   
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Figure. 4.7.  Mass spectrometry of 705 negative control oligonucleotide 
samples.   
 
Mass spectrometry was performed to determine the oligonucleotide 
chemistry of a 705 negative control sample (705Unk).  Known 705 
oligonucleotide samples of 2’-O-methyl (705OMe) and 2’-O-methoxyethoxy 
(705MOE) chemistry were tested for comparison.  Mass spectrometry profile 
of the 705Unk sample was identical to the 705MOE sample.  Analysis was 
performed by the University of North Carolina’s Michael Hooker Proteomics 
Core Facility.  
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  We were unable to directly link splice switching of PSMA by these SSOs 
with changes in malignancy of LNCaP cells as measured by cellular proliferation 
and apoptosis.  However, this does not remove PSMA from being considered a 
factor or contributor of prostate cancer initiation or progression.  Although the 
SSOs used here were efficient in altering PSMA mRNA levels, the modest 
change in protein level induced may not have been sufficient to detect any real 
effects in culture.  As mentioned previously, PSMA SSOs of other chemistries 
may be able to lower EC50 values and produce a more significant change in 
PSMA protein levels.  Also, it would be informative to separately introduce PSMA 
splice variants into cell lines that do not natively express PSMA and test for 
specific cellular changes.  This would remove background effects of due to the 
presence of other variants, but not be able to directly address the consequence 
of splice ratios.      
To speculate into PSMA’s possible contribution to prostate malignancy, its 
cell surface presentation puts it into the categories of extracellular signal 
transducer, surface membrane receptor, or extracellular matrix protein.  Cell 
surface signaling for growth stimulation, angiogenesis, and tissue invasion can 
be exploited to sustain cancer cells.   As detailed earlier, PSMA is capable of 
binding a ligand outside of the cell and signal intracellularly for the initiation of 
internalization.  Although its intracellular domain is very small, its five C-terminal 
amino acids are required for this internalization; PSMA is capable of at least this 
level of signal transduction.  Overexpression of the membrane bound form of 
PSMA in prostate cancer compared to the cytosolic variant is consistent with, but 
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not evidence of it being utilized by cancer cells for survival, growth, or invasion 
signaling.  There is one published report that PSMA is able to act as a receptor 
molecule by transporting extracellular cargo into the cytoplasm (Lupold, Hicke et 
al. 2002), also a study in progress demonstrates that nucleic aptamer conjugates 
targeted for uptake by PSMA are internalized by LNCaP cells, enter the 
cytoplasm, and downregulate specific mRNA transcripts (Giangrande and 
Sullenger, unpublished data).  More research is required to define PSMA’s 
receptor capacity.  PSMA may prove to be important in physical cellular linkages 
as part of the extracellular matrix superstructure.  Surprisingly, Ghosh et al. 
determined that expression of PSMA in PC3 cells decreased invasiveness 
(Ghosh, Wang et al. 2005).  Although this is opposite of the expectation, it does 
suggest that PSMA has some role in the physical links that cancer cells make for 
tissue invasion and metastasis.        
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Summary of Dissertation Results  
Splice switching oligonucleotides have been successfully used with 
several gene targets for the manipulation of alternatively spliced variants (see 
Chapter 1).  Results presented here verify that we are now able to add PSMA to 
this growing list by targeting its pre-mRNA with SSOs of OMe and MOE 
chemistries.  SSOs 1, 6, and 18 targeted to the 5’ splice sites of exons 1, 6, and 
18, respectively, were able to induce a decline in full length PSMA mRNA and 
increase mRNA levels of PSM’, PSMA∆6, and PSMA∆18 (Chapter 3).  In 
addition, splice switching to the endogenously less prominent variants in LNCaP 
cells caused a decline in membrane bound PSMA protein.  Treatment with SSO1 
for 48 hours also increased PSM’ protein levels in the cytoplasm (Chapter 3).  A 
functional assay measuring PSMA’s NAALADase activity verified splice switching 
at the protein level and, importantly, indicated that the cytoplasmic PSM’ retains 
functional activity despite its lack of glycosylation (Chapter 3).  We attempted to 
link the change in PSMA splice variant levels from SSO treatment to a change in 
properties of LNCaP cellular malignancy by testing levels of cellular proliferation 
and apoptosis post SSO transfection (Chapter 4).  Our study was based on the 
observation that PSMA splice ratios are naturally altered in prostate cancer 
compared with normal prostate tissue (see Chapter 1 for a detailed explanation), 
i.e. the PSM’/PSMA mRNA ratio decreases from normal and benign prostate 
tissue to prostate cancer and continues to decrease with an increase in cancer 
grade (Chapter 1).  However, we were not able to correlate PSMA specific splice 
switching by our SSOs with cellular proliferation and apoptosis levels as 
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measured by three different assays (Chapter 4).                                                                
Jjjjjjjjjjjjjj It is possible that the amount of splice switching we were able to induce 
at the protein level is not adequate enough to detect any PSMA specific changes 
in LNCaP cells; testing SSOs of different chemistries and concentrations may 
identify more efficient SSOs that are able to significantly alter PSMA protein 
levels.  Moreover, future studies into PSMA’s function in prostate tissue and 
tumor neovasculature will be invaluable in determining whether our splice 
switching technique targeted at PSMA pre-mRNA will be useful toward the 
treatment of prostate and other types of cancers.  It is also a definite possibility 
that native changes in PSMA splicing based on prostate tissue malignancy are a 
consequence or effect of cellular changes rather than a causative factor.  If that 
is the case, SSO technology used here would not be a useful therapeutic. 
However, PSMA splice ratio could still be used as a diagnostic marker in prostate 
cancer in conjunction with screening by PSA and other markers. 
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